<SEC-DOCUMENT>0001193805-21-000331.txt : 20210304
<SEC-HEADER>0001193805-21-000331.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210304162609
ACCESSION NUMBER:		0001193805-21-000331
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20210302
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICAD INC
		CENTRAL INDEX KEY:			0000749660
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				020377419
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-09341
		FILM NUMBER:		21714504

	BUSINESS ADDRESS:	
		STREET 1:		98 SPIT BROOK ROAD, SUITE 100
		CITY:			NASHUA
		STATE:			NH
		ZIP:			03062
		BUSINESS PHONE:		603-882-5200

	MAIL ADDRESS:	
		STREET 1:		98 SPIT BROOK ROAD, SUITE 100
		CITY:			NASHUA
		STATE:			NH
		ZIP:			03062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HOWTEK INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e620354_8k-icad.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ICAD="http://icadmed.com/20210302">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_ICAD_icadmed.com_20210302 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20210302_20210302 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000749660 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityCentralIndexKey">0000749660</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="icad-20210302.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2021-03-02to2021-03-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749660</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-02</xbrli:startDate>
        <xbrli:endDate>2021-03-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20210302__20210302_zlydUB37ZkZ6"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TO SECTION 13 OR 15(d) OF THE </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of report (Date of earliest event
reported): <span id="xdx_909_edei--DocumentPeriodEndDate_c20210302__20210302_zQSrsFhqTpXc"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 2, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20210302__20210302_zWjB1oXY8HL3"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityRegistrantName">iCAD, INC.</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified
in Its Charter) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20210302__20210302_z8hHkDDNaszh"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or Other Jurisdiction of Incorporation)
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 55%"><b><span id="xdx_90E_edei--EntityFileNumber_c20210302__20210302_z702WLbCVks9"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityFileNumber">001-09341</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20210302__20210302_z6wKsA5OUH7h"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityTaxIdentificationNumber">02-0377419</ix:nonNumeric></span></b></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS Employer</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
<tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20210302__20210302_zIQBnGxtnQHd"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityAddressAddressLine1">98 Spit Brook Road</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20210302__20210302_zZTzutXe2MCg"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20210302__20210302_z0c0WeX4Tlz7"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityAddressCityOrTown">Nashua</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20210302__20210302_zDqVZZlJbDHc"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New Hampshire</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20210302__20210302_zQmodqvi2Vyd"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityAddressPostalZipCode">03062</ix:nonNumeric></span></b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Zip Code)</b></p></td></tr>
<tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><b>(Address of Principal Executive Offices)</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--CityAreaCode_c20210302__20210302_zIeJigcxxiMf"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:CityAreaCode">(603)</ix:nonNumeric></span> <span id="xdx_90A_edei--LocalPhoneNumber_c20210302__20210302_zT6wdyBZi3x6"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:LocalPhoneNumber">882-5200</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s Telephone Number,
Including Area Code) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityInformationFormerLegalOrRegisteredName_c20210302__20210302_zLsgummCd4Z6"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:EntityInformationFormerLegalOrRegisteredName">Not Applicable</ix:nonNumeric> </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed
Since Last Report) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--WrittenCommunications_c20210302__20210302_zpUaSVK4sBx5"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--SolicitingMaterial_c20210302__20210302_zed6m5GDChab"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--PreCommencementTenderOffer_c20210302__20210302_zYUtGN6F9g5i"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20210302__20210302_zWHxmOkhi5e"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 30%; font-size: 10pt; text-align: center"><b>Title of each class</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 25%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Trading</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>symbol(s)</b></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 30%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name of each exchange</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>on which registered</b></p></td></tr>
<tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><b><span id="xdx_90C_edei--Security12bTitle_c20210302__20210302_z4dTo8qMI4Y6"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:Security12bTitle">Common Stock, $0.01 par value</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><b><span id="xdx_902_edei--TradingSymbol_c20210302__20210302_zL75AZKBhKsb"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" name="dei:TradingSymbol">ICAD</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><b><span id="xdx_907_edei--SecurityExchangeName_c20210302__20210302_zM4chhlU7geh"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></b></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20210302__20210302_zKUrzeuxzwjj"><ix:nonNumeric contextRef="From2021-03-02to2021-03-02" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; font-size: 10pt"><b>Item 1.01. Entry Into a Material Definitive Agreement.</b></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 2, 2021, iCAD, Inc. (the &#8220;Company&#8221;) entered
into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Guggenheim Securities, LLC, as representative of
the several underwriters identified in Schedule I thereto (the &#8220;Underwriters&#8221;), in connection with the Company&#8217;s
underwritten public offering (the &#8220;Offering&#8221;) of 1,222,222 shares (the &#8220;Firm Shares&#8221;) of the Company&#8217;s
common stock, $0.01 par value per share (the &#8220;Common Stock&#8221;), at a public offering price of $18.00 per share. Under
the terms of the Underwriting Agreement, the Company granted the Underwriters an option (the &#8220;Option&#8221;), exercisable
for 30 days, to purchase up to an additional 171,516 shares of Common Stock (together with the Firm Shares, the &#8220;Shares&#8221;),
which Option was exercised in full on March 3, 2021. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering is being made pursuant to a prospectus supplement
dated March 2, 2021 and an accompanying prospectus, pursuant to a registration statement on Form S-3 (File No. 333-235887) initially
filed by the Company on January 10, 2020 and declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;)
on January 31, 2020, and a registration statement filed on March 2, 2021 pursuant to Rule 462(b) (File No. 333-253808) of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;) which became immediately effective upon filing pursuant to the Securities
Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Underwriting Agreement contains customary representations,
warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters,
including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations,
warranties, and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific
dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting
parties. In exchange for the Underwriters&#8217; services, the Company agreed to sell the Shares to the Underwriters at a purchase
price of $16.92 per share and to reimburse the representative of the Underwriters for up to $125,000 of its expenses in connection
with the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The net proceeds to the Company from the Offering will be approximately
$23.2 million following the exercise of the Option in full, after deducting underwriting discounts and commissions and estimated
offering expenses payable by the Company. The Offering is scheduled to close on March 5, 2021, subject to the satisfaction of customary
closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing summary of the Underwriting Agreement is qualified
in its entirety by reference to the Underwriting Agreement attached hereto as Exhibit 1.1 and which is hereby incorporated by reference.
Dentons US LLP, counsel to the Company, delivered an opinion as to legality of the issuance and sale of the Shares in the Offering,
a copy of which is attached hereto as Exhibit 5.1 and is hereby incorporated by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.02. Termination of Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 2, 2021, the Company terminated its Equity Distribution
Agreement entered into on March 30, 2020 with JMP Securities LLC. Under the Equity Distribution Agreement, the Company was permitted
to offer and sell its common stock, par value $0.01 per share, from time to time during the term of the Equity Distribution Agreement
through JMP Securities LLC, acting as agent. The Company received approximately $6.1 million in net proceeds from sales of its
common stock pursuant to the Equity Distribution Agreement prior to its termination. No material early termination penalties were
incurred by the Company in connection therewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01. Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 2 and March 3, 2021, the Company issued press releases
announcing the launch of the Offering and the pricing of the Offering, respectively. Copies of the press releases are furnished
as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information disclosed under this Item 7.01, including
Exhibits 99.1 and 99.2, is being furnished for informational purposes only and shall not be deemed &#8220;filed&#8221; for purposes
of Section 18 of Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities
of that section, and shall not be deemed to be incorporated by reference into any of the Company&#8217;s previous or future filings
under the Securities Act or the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 7%">
<div style="border-bottom: black 1pt solid; padding: 0in">

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit No.</b></p>
</div></td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 88%">
        <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit Description</b></p></td></tr>
<tr>
    <td style="font-size: 10pt">1.1</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><a href="e620354_1-1.htm">Underwriting Agreement, dated March 2, 2021, by and between iCAD, Inc. and Guggenheim Securities, LLC</a></td></tr>
<tr>
    <td style="vertical-align: top; font-size: 10pt">5.1</td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="e620354_5-1.htm">Opinion of Dentons US LLP</a></td></tr>
<tr>
    <td style="vertical-align: top; font-size: 10pt">23.1 </td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="e620354_5-1.htm">Consent of Dentons US LLP (contained in Exhibit 5.1)</a></td></tr>
<tr>
    <td style="vertical-align: top; font-size: 10pt">99.l</td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="e620354_99-1.htm">Press release dated March 2, 2021</a></td></tr>
<tr>
    <td style="vertical-align: top; font-size: 10pt">99.2</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="e620354_99-2.htm">Press release dated March 3, 2021</a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>SIGNATURES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">iCAD, INC.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Registrant)</p></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="width: 57%">&#160;</td>
    <td style="vertical-align: top; width: 3%; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 39%; font-size: 10pt">/s/ Michael Klein</td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Klein</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 4, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LbpuKrI7HTrEKTJEvC1blOLWjLT+PZJvad0QQyAk53w5QgxERitdI8NpUeRwwKatlUMo8IyMpkTvSNebBPws8KKtY2Vct/7AlDyDnpkMp6W/d867tlglEMajcDyKJEiZxDOYb0Xw1VMyZ12hcVrVoEwFe6aWNTrFr/7DQT3JUPPqko7IVpNJQA7DXn5DFMoIdnRXD+KrhTxPRTDoKhAZ0639xtysowaWNTY+y/bov4MP1plJDA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>e620354_1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">1,222,222 Shares of
Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ICAD, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 2, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Guggenheim Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As Representative
of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">several Underwriters
named in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Schedule I attached
hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c/o Guggenheim Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">330 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">iCAD, Inc., a corporation
organized and existing under the laws of the State of Delaware (the &ldquo;<B>Company</B>&rdquo;), proposes, subject to the terms
and conditions stated herein, to issue and sell to the several underwriters named in <U>Schedule I</U> hereto (the &ldquo;<B>Underwriters</B>&rdquo;)
an aggregate of 1,222,222 shares (the &ldquo;<B>Firm Shares</B>&rdquo;) of its common stock, par value $0.01 per share (the &ldquo;<B>Common
Stock</B>&rdquo;). The Company also proposes to issue and sell to the several Underwriters up to an additional 171,516 shares (the
&ldquo;<B>Additional Shares</B>&rdquo;) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The
Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the &ldquo;<B>Shares</B>.&rdquo;
Guggenheim Securities, LLC (&ldquo;<B>Guggenheim Securities</B>&rdquo;) is acting as representative (the &ldquo;<B>Representative</B>&rdquo;)
of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the &ldquo;<B>Offering</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this underwriting
agreement (the &ldquo;<B>Agreement</B>&rdquo;), the following defined terms shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &ldquo;<B>Registration
Statement</B>&rdquo; means the registration statement on Form S-3 (File No. 333-235887), including the exhibits, schedules and
financial statements and any prospectus supplement relating to the Offering that is filed with the Securities and Exchange Commission
(the &ldquo;<B>Commission</B>&rdquo;) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder (the &ldquo;<B>Securities Act</B>&rdquo;) and deemed part of such registration statement pursuant to Rule
430B under the Securities Act, as amended on each Effective Date (as defined below), and, in the event any post-effective amendment
thereto or any registration statement and any amendments thereto filed pursuant to Rule 462(b) under the Securities Act (a &ldquo;<B>Rule
462(b) Registration Statement</B>&rdquo;) becomes effective prior to the Closing Date (as defined in Section&nbsp;2(b) hereof),
shall also mean such registration statement as so amended or such Rule 462(b) Registration Statement, as the case may be<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &ldquo;<B>Effective
Date</B>&rdquo; means, with respect to the Registration Statement, each date and time that such Registration Statement, and any
post-effective amendment or amendments thereto or any Rule 462(b) Registration Statement became or becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR>
    <TD></TD></TR>
</TABLE>
<P STYLE="margin: 0pt 0; text-indent: 0.5in">The &ldquo;<B>Base Prospectus</B>&rdquo; means the base prospectus contained in the
Registration Statement at the date and time that this Agreement is executed and delivered by the parties hereto.</P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &ldquo;<B>Preliminary
Prospectus</B>&rdquo; means any preliminary prospectus supplement to the Base Prospectus which is used prior to the filing of the
Prospectus (as defined below), together with the Base Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &ldquo;<B>Prospectus</B>&rdquo;
means the final prospectus supplement relating to the Offering that is first filed pursuant to Rule 424(b) under the Securities
Act, together with the Base Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &ldquo;<B>Pricing
Disclosure Package</B>&rdquo; shall mean (i)&nbsp;the Base Prospectus, (ii)&nbsp;the Preliminary Prospectus used most recently
prior to the Applicable Time (as defined below), (iii) any issuer free writing prospectus, as defined in Rule 433 under the Securities
Act (an &ldquo;<B>Issuer Free Writing Prospectus</B>&rdquo;), identified in <U>Schedule II</U> hereto, (iv)&nbsp;the information
included on <U>Schedule III</U> hereto, and (v)&nbsp;any other free writing prospectus, as defined in Rule 405 under the Securities
Act (a &ldquo;<B>Free Writing Prospectus</B>&rdquo;), that the parties hereto shall hereafter expressly agree in writing to treat
as part of the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used herein, &ldquo;<B>Applicable
Time</B>&rdquo; is 9:00 p.m. (New York City time) on March 2, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used herein, &ldquo;<B>Road
Show</B>&rdquo; means a &ldquo;road show&rdquo; (as defined in Rule 433 under the Securities Act) relating to the offering of the
Shares contemplated hereby that is a &ldquo;written communication&rdquo; (as defined in Rule 405 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this
Agreement to the Registration Statement, any Preliminary Prospectus, the Base Prospectus and the Prospectus shall include the documents
incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules
and other information that are &ldquo;<B>contained in</B>,&rdquo; &ldquo;<B>included in</B>,&rdquo; &ldquo;<B>filed with</B>,&rdquo;
&ldquo;<B>stated in</B>&rdquo; or &ldquo;<B>part of</B>&rdquo; the Registration Statement, the Rule 462(b) Registration Statement,
any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, and all other references of like import, shall be
deemed to mean and include all such financial statements and schedules and other information that is or is deemed to be incorporated
by reference in the Registration Statement, the Rule 462(b) Registration Statement, any Preliminary Prospectus, the Base Prospectus,
the Pricing Disclosure Package or the Prospectus, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this
Agreement to amendments or supplements to the Registration Statement, the Rule 462(b) Registration Statement, any Preliminary Prospectus,
the Pricing Disclosure Package or the Prospectus shall be deemed to mean and include the filing of any document under the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;)
that is or is deemed to be incorporated by reference in the Registration Statement, the Rule 462(b) Registration Statement, any
Preliminary Prospectus, the Pricing Disclosure Package, or the Prospectus, as the case may be. All references in this Agreement
to the Registration Statement, any Preliminary Prospectus, the Base Prospectus or the Prospectus, any amendments or supplements
to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its
Electronic Data Gathering, Analysis and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Representations and Warranties of the Company</U>. The Company represents and warrants to, and agrees with, each
of the Underwriters as of the date hereof, the Applicable Time, the Closing Date (as hereinafter defined) and any Additional Closing
Date (as hereinafter defined) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Registration Statement has been declared effective by the Commission under the Securities Act. The Company has
complied, to the Commission&rsquo;s satisfaction, with all requests of the Commission for additional or supplemental information,
if any. No stop order suspending the effectiveness of either Registration Statement is in effect and no proceedings for such purpose
have been instituted or are pending or, to the Company&rsquo;s knowledge, are contemplated or threatened by the Commission. At
the time the Registration Statement was originally filed with the Commission, the Company met the then-applicable requirements
for use of Form S-3 under the Securities Act. The documents incorporated or deemed to be incorporated by reference in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, at the time they were or hereafter are filed with the Commission,
or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto,
as of the applicable Effective Date, complied and, until such time as the Underwriters are no longer required to deliver a Prospectus
in order to confirm sales of the Shares, will comply in all material respects with the Securities Act and the rules and regulations
of the Commission thereunder (the &ldquo;<B>Rules and Regulations</B>&rdquo;). The Preliminary Prospectus and the Prospectus, at
the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and
the Rules and Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and
the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to
EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable,
will not contain, as of the date of such amendment or supplement, an untrue statement of a material fact or omitted or will omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however,
that this representation and warranty shall not apply to any information contained in or omitted from the Registration Statement
or any amendment thereto in reliance upon and in conformity with information furnished in writing to the Company by or on behalf
of any Underwriter through the Representative specifically for use therein. The parties hereto agree that such information provided
by or on behalf of any Underwriter through the Representative consists solely of the material referred to in Section&nbsp;19 hereof.
Each &ldquo;forward-looking statement&rdquo; (within the meaning of Section&nbsp;27A of the Securities Act or Section&nbsp;21E
of the Exchange Act) contained or incorporated by reference in the Registration Statement, the Preliminary Prospectus or the Prospectus
has been made or reaffirmed with a reasonable basis and has been disclosed in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Pricing Disclosure Package, as of the Applicable Time, did not contain an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Prospectus will not, as of its date, as of the Closing Date or as of any Additional Closing
Date, contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. Each Issuer Free Writing Prospectus complies
in all material respects with the applicable provisions of the Securities Act and the Rules and Regulations, and does not conflict
with the information contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus, and does not contain
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances in which they were made, not misleading. No representation and warranty is made in this Section&nbsp;1(d)
with respect to any information contained in or omitted from the Pricing Disclosure Package or the Prospectus in reliance upon
and in conformity with information furnished in writing to the Company by or on behalf of any Underwriter through the Representative
specifically for use therein. The parties hereto agree that such information provided by or on behalf of any Underwriter through
the Representative consists solely of the material referred to in Section&nbsp;19 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the earliest time (i) after the filing of the Registration Statement that the Company or another offering participant
made a bona fide offer (within the meaning of Rule 164(h)(2) of the Rules) of the Shares and (ii) at the date hereof, the Company
was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405 of the Rules, including (but not limited to) the
Company or any subsidiary in the preceding three years not having been convicted of a felony or misdemeanor or having been made
the subject of a judicial or administrative decree or order as described in Rule 405 of the Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Each Issuer Free Writing Prospectus conformed or will conform in all material respects to the requirements of the
Securities Act and the Rules and Regulations on the date of first use, and the Company has complied with the requirements of Rule
433 under the Securities Act with respect to each Issuer Free Writing Prospectus including, without limitation, all prospectus
delivery, filing, record retention and legending requirements applicable to any such Issuer Free Writing Prospectus. The Company
has not (i)&nbsp;distributed any offering material in connection with the Offering other than any Preliminary Prospectus, the Prospectus,
and any Issuer Free Writing Prospectus set forth on <U>Schedule II</U> hereto, or (ii)&nbsp;filed, referred to, approved, used
or authorized the use of any &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under the Securities Act with respect
to the Offering or the Shares, except for any Issuer Free Writing Prospectus set forth in <U>Schedule II</U> hereto and any electronic
Road Show previously approved by the Representative. The Company has retained in accordance with the Securities Act and the Rules
and Regulations all Issuer Free Writing Prospectuses that were not required to be filed pursuant to the Securities Act and the
Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company (i) has not alone engaged in any Testing-the-Waters Communications, other than Testing-the-Waters Communications
with the prior consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A
under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act
and (ii) has not authorized anyone other than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms
that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company
has not distributed any Written Testing-the-Waters Communications (as defined below) other than those listed on Schedule V hereto.
&ldquo;<B>Written Testing-the-Waters Communication</B>&rdquo; means any Testing-the-Waters Communication that is a written communication
within the meaning of Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>BDO USA, LLP, which has expressed its opinion with respect to the financial statements (which term as used in this
Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Pricing Disclosure
Package or the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the
Exchange Act, and the rules of the Public Company Accounting Oversight Board (&ldquo;<B>PCAOB</B>&rdquo;), (ii) in compliance with
the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities
Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked
and who has not requested such registration to be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Subsequent to the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure
Package or the Prospectus, except as disclosed therein, (i)&nbsp;the Company has not declared or paid any dividends, or made any
other distribution of any kind, on or in respect of its capital stock, (ii)&nbsp;there has not been any material change in the
capital stock or long-term or short-term debt of the Company or its subsidiaries listed in <U>Exhibit A</U> hereto (the &ldquo;<B>Subsidiaries</B>&rdquo;),
(iii) there have been no transactions entered into by the Company or the Subsidiaries, other than in the ordinary course of business,
which are material with respect to the Company and the Subsidiaries, taken as a whole, (iv)&nbsp;neither the Company nor any Subsidiary
has sustained any material loss or interference with its business or properties from fire, explosion, flood, earthquake, hurricane,
accident or other calamity, whether or not covered by insurance, or from any labor dispute or any legal or governmental proceeding,
and (v)&nbsp;there has not been any material adverse change, or any development involving a prospective material adverse change,
whether or not arising from transactions in the ordinary course of business, in or affecting the business, management, condition
(financial or otherwise), results of operations, stockholders&rsquo; equity, properties or prospects of the Company and the Subsidiaries,
taken as a whole (a &ldquo;<B>Material Adverse Change</B>&rdquo;). Since the date of the latest balance sheet included, or incorporated
by reference, in the Registration Statement, the Pricing Disclosure Package or the Prospectus, neither the Company nor any Subsidiary
has incurred or undertaken any liabilities or obligations, whether direct or indirect, liquidated or contingent, matured or unmatured,
or entered into any transactions, including any acquisition or disposition of any business or asset, which are material to the
Company and the Subsidiaries, taken as a whole, except for liabilities, obligations and transactions which are disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company has an authorized capitalization as set forth in the Pricing Disclosure Package and the Prospectus, and
all of the issued and outstanding shares of capital stock of the Company are fully paid and non-assessable and have been duly authorized
and validly issued, in compliance with all applicable state, federal and foreign securities laws and not in violation of or subject
to any preemptive or similar right that entitles any person to acquire from the Company or the Subsidiaries any Common Stock or
other security of the Company or any security convertible into, or exercisable or exchangeable for, Common Stock or any other such
security of the Company (any &ldquo;<B>Relevant Security</B>&rdquo;), except for such rights as may have been fully satisfied or
waived prior to the effectiveness of the Registration Statement. All of the issued shares of capital stock of or other ownership
interests in the Subsidiaries owned, directly or indirectly, by the Company have been duly authorized and validly issued and are
fully paid and non-assessable and are owned directly or indirectly by the Company free and clear of any lien, charge, mortgage,
pledge, security interest, claim, equity, trust or other encumbrance, preferential arrangement, defect or restriction of any kind
whatsoever (any &ldquo;<B>Lien</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Shares to be delivered on the Closing Date and any Additional Closing Date, if any, have been duly authorized
and, when issued and delivered in accordance with this Agreement, will be validly issued, fully paid and non-assessable<B>, </B>will
have been issued in compliance with all applicable state, federal and foreign securities laws and will not have been issued in
violation of or subject to any preemptive or similar right that entitles any person to acquire any Relevant Security from the Company.
The Common Stock and the Shares conform to the descriptions thereof contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company has no outstanding warrants, options to purchase, or any preemptive rights or other rights to subscribe for or to purchase,
or any contracts or commitments to issue or sell, any Relevant Security. No holder of any Relevant Security has any rights to require
registration under the Securities Act of any Relevant Security in connection with the offer and sale of the Shares contemplated
hereby, except for any such rights that have either been fully complied with by the Company or effectively waived by the holders
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and each Subsidiary has been duly organized and validly exists as a corporation, partnership or limited
liability company (as the case may be) in good standing under the laws of its jurisdiction of organization (to the extent such
good standing concept exists in such jurisdiction) and has corporate, partnership or limited liability company power and authority
(as the case may be) to own or lease its property and conduct its business as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus. The Company and each Subsidiary is qualified to do business and is in good standing as a
foreign corporation, partnership or limited liability company (as the case may be) in each jurisdiction (to the extent such good
standing concept exists in such jurisdiction) in which the character or location of its properties (owned, leased or licensed)
or the nature or conduct of its business makes such qualification necessary, except for those failures to be so qualified or in
good standing (to the extent such good standing concept exists in such jurisdiction) which (individually and in the aggregate)
would not reasonably be expected to have a material adverse effect on (i)&nbsp;the business, management, condition (financial or
otherwise), results of operations, stockholders&rsquo; equity, properties or prospects of the Company and the Subsidiaries, taken
as a whole; or (ii)&nbsp;the ability of the Company to consummate the Offering or any other transaction contemplated by this Agreement
or the Registration Statement, the Pricing Disclosure Package and the Prospectus (a &ldquo;<B>Material Adverse Effect</B>&rdquo;).
The certificate or articles of incorporation, by-laws, partnership agreement, limited liability company agreement or other constitutive
and organizational documents (as the case may be) of the Company and the Subsidiaries comply with the requirements of applicable
law and are in full force and effect. The Subsidiaries are the only &ldquo;subsidiaries&rdquo; of the Company (within the meaning
of Rule 405 under the Securities Act.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Neither the Company nor any Subsidiary (i)&nbsp;is in violation of its certificate or articles of incorporation,
by-laws, certificate of formation, limited liability company agreement, partnership agreement or other organizational documents,
(ii)&nbsp;is in default under, and no event has occurred which, with notice or lapse of time or both, would constitute a default
under or result in the creation or imposition of any Lien upon any property or assets of the Company or the Subsidiaries pursuant
to, any indenture, mortgage, deed of trust, note, lease, loan agreement or other agreement or instrument to which it is a party
or by which it is bound or to which any of its property or assets is subject, or (iii)&nbsp;is in violation of any statute, law,
rule, regulation, ordinance, directive, judgment, writ, decree or order of any court or judicial, regulatory or other legal or
governmental agency or body, foreign or domestic, having jurisdiction over the Company or the Subsidiaries except (in the case
clauses (ii)&nbsp;and (iii) above) for violations or defaults that would not (individually or in the aggregate) reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and the Subsidiaries have all requisite power and authority, and all necessary consents, approvals, authorizations,
orders, registrations, qualifications, licenses, filings and permits of, with and from all judicial, regulatory and other legal
or governmental agencies and bodies and all third parties, foreign and domestic (collectively, the &ldquo;<B>Consents</B>&rdquo;),
to own, lease and operate its properties and conduct its business as it is now being conducted and as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, and each such Consent is valid and in full force and effect, except
in each case as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has
received notice of any investigation or proceedings which, if decided adversely to the Company or the Subsidiaries, would reasonably
be expected to result in the revocation of, or imposition of a materially burdensome restriction on, any such Consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>This Agreement has been duly and validly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The issue and sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus), the compliance by the Company with this Agreement and the consummation
of the transactions contemplated hereby and by the Registration Statement, the Pricing Disclosure Package and the Prospectus do
not and will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms and provisions of, or constitute
a default (or an event which with notice or lapse of time, or both, would constitute a default) under, or result in the creation
or imposition of any Lien upon any property or assets of the Company or the Subsidiaries pursuant to, any indenture, mortgage,
deed of trust, note, lease, loan agreement or other agreement, instrument, franchise, license or permit to which the Company or
any Subsidiary is a party or by which the Company or the Subsidiaries or their respective properties, operations or assets may
be bound, (ii)&nbsp;violate or conflict with any provision of the certificate or articles of incorporation, by-laws, certificate
of formation, limited liability company agreement, partnership agreement or other organizational documents (as the case may be)
of the Company or the Subsidiaries, or (iii)&nbsp;violate or conflict with any statute, law, rule, regulation, ordinance, directive,
judgment, writ, decree or order of any court or judicial, regulatory, administrative or other legal or governmental agency or body
(including, without limitation, the U.S. Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;), domestic or foreign, having
jurisdiction over the Company or the Subsidiaries, except (in the case of clauses (i)&nbsp;and (iii) above) as would not reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>No Consent is required for the execution, delivery and performance by the Company of this Agreement, the issue and
sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus) and the consummation by the Company of the transactions contemplated hereby and by the Registration
Statement, the Pricing Disclosure Package and the Prospectus, except the registration under the Securities Act of the Shares, such
Consents as may be required by the Nasdaq Stock Market LLC (&ldquo;<B>Nasdaq</B>&rdquo;) in regards to the listing of the Shares
and under applicable state securities or blue sky laws and such other Consents as have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>There is no judicial, regulatory, arbitral or other legal or governmental proceeding or other litigation or arbitration,
domestic or foreign, pending to which the Company or any Subsidiary is a party or of which any property, operations or assets of
the Company or the Subsidiaries is the subject which, individually or in the aggregate, if determined adversely to the Company
or any Subsidiary, would reasonably be expected to have a Material Adverse Effect on the consummation of the transactions contemplated
in this Agreement or the performance by the Company of its obligations hereunder; to the Company&rsquo;s knowledge, no such proceeding,
litigation or arbitration is threatened or contemplated; and the defense of all such proceedings, litigation and arbitration against
or involving the Company or any Subsidiary would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The financial statements, including the notes thereto, and the supporting schedules included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus present fairly in all material respects the consolidated
financial position as of the dates indicated and the cash flows and results of operations for the periods specified of the Company
and the Subsidiaries; said financial statements have been prepared in conformity with United States generally accepted accounting
principles (&ldquo;<B>GAAP</B>&rdquo;) applied on a consistent basis throughout the periods involved; and the supporting schedules,
if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus present fairly in all material
respects in accordance with GAAP the information required to be stated therein. No other historical or pro forma financial statements
or supporting schedules are required to be included in the Registration Statement, the Pricing Disclosure Package or the Prospectus
by the Securities Act, the Exchange Act or the Rules and Regulations. The other financial and statistical information included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus present fairly in
all material respects the information included therein and have been prepared on a basis consistent with that of the financial
statements that are included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the
Prospectus and the books and records of the respective entities presented therein. All disclosures contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, or incorporated by reference therein, regarding &ldquo;non-GAAP financial
measures&rdquo; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange
Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. The interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the
Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s
rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>There are no contracts or documents which are required to be described in the Registration Statement, the Pricing
Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described
and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and the Subsidiaries maintain a system of internal accounting and other controls sufficient to provide
reasonable assurances that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations,
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
accountability for assets, (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization, (iv)&nbsp;the recorded accounting for assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the
information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and guidelines
applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f)
under the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company&rsquo;s principal
executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company&rsquo;s
internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal
control over financial reporting. Since the date of the latest audited financial statements included or incorporated by reference
in the Pricing Disclosure Package, there has been no change in the Company&rsquo;s internal control over financial reporting that
has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange
Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure
that material information relating to the Company and the Subsidiaries is made known to the Company&rsquo;s principal executive
officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or executive
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002
and the rules and regulations promulgated in connection therewith (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;), including Section&nbsp;402
related to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and the Shares have
been approved for listing on the Nasdaq Capital Market, subject to completion of the issuance of the Shares pursuant to this Agreement,
and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under
the Exchange Act or delisting the Shares from the Nasdaq Capital Market, nor has the Company received any notification that the
Commission or Nasdaq is contemplating terminating such registration or listing. To the Company&rsquo;s knowledge, it is in compliance
with all applicable listing requirements of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>To the Company&rsquo;s knowledge, no relationship, direct or indirect, exists between or among any of the Company
or any affiliate of the Company, on the one hand, and any director, officer, shareholder, customer or supplier of the Company or
any affiliate of the Company, on the other hand, which is required by the Securities Act or the Exchange Act to be described in
the Registration Statement or the Prospectus that is not so described as required. There are no outstanding loans, advances (except
normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company to or for
the benefit of any of the officers or directors of the Company or any of their respective family members. The Company has not,
in violation of the Sarbanes-Oxley Act, directly or indirectly, including through any affiliate of the Company, extended or maintained
credit, arranged for the extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any director
or executive officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Neither the Company nor any of its affiliates (within the meaning of Rule 144 under the Securities Act) has taken,
directly or indirectly, any action which constitutes or is designed to cause or result in, or which would reasonably be expected
to constitute, cause or result in, the stabilization or manipulation of the price of any security to facilitate the sale or resale
of the Shares or to result in a violation of Regulation M under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Neither the Company nor any of its affiliates (within the meaning of Rule 144 under the Securities Act) has, prior
to the date hereof, made any offer or sale of any securities which would be &ldquo;integrated&rdquo; (within the meaning of the
Securities Act and the Rules and Regulations) with the offer and sale of the Shares pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>All of the information provided to the Underwriters or to counsel for the Underwriters by the Company and, to the
Company&rsquo;s knowledge, its officers, directors and the holders of any securities (debt or equity) or options to acquire any
securities of the Company in connection with the offering of the Shares is true, complete and correct in all material respects
and compliant with Financial Industry Regulatory Authority, Inc.&rsquo;s (&ldquo;<B>FINRA</B>&rdquo;) rules and, to the Company&rsquo;s
knowledge, any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules
is true, complete and correct in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The statements set forth in the Pricing Disclosure Package and Prospectus under the caption &ldquo;Description of
Capital Stock&rdquo;, insofar as it purports to constitute a summary of the terms of the Common Stock, and under the caption &ldquo;Risk
Factors&rdquo;, insofar as it purports to describe the provisions of the laws and documents referred to therein, are accurate and
complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company is not and, at all times up to and including consummation of the transactions contemplated by this Agreement,
and after giving effect to application of the net proceeds of the Offering as described in the Pricing Disclosure Package and the
Prospectus, will not be, required to register as an &ldquo;investment company&rdquo; under the Investment Company Act of 1940,
as amended, and is not and will not be an entity &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo; within the meaning
of such act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>There are no contracts, agreements or understandings between the Company and any person that would give rise to a
valid claim against the Company or any Underwriter for a brokerage commission, finder&rsquo;s fee or other like payment in connection
with the transactions contemplated by this Agreement or, to the Company&rsquo;s knowledge, any arrangements, agreements, understandings,
payments or issuance with respect to the Company or any of its officers, directors, shareholders, partners, employees, subsidiaries
or affiliates that may affect the Underwriters&rsquo; compensation, as determined by FINRA Rule 5110.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and each Subsidiary owns or leases all such properties as are necessary to the conduct of its business as presently
operated and as proposed to be operated as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
The Company and the Subsidiaries have good and marketable title in fee simple to all real property and good and marketable title
to all personal property owned by them, in each case free and clear of any and all Liens except such as are described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus or such as do not (individually or in the aggregate) materially affect
the value of such property or materially interfere with the use made or proposed to be made of such property by the Company and
the Subsidiaries; and any real property and buildings held under lease or sublease by the Company and the Subsidiaries are held
by them under valid, subsisting and enforceable leases with such exceptions as are not material to, and do not materially interfere
with, the use made and proposed to be made of such property and buildings by the Company and the Subsidiaries. Neither the Company
nor any Subsidiary has received any notice of any claim adverse to its ownership of any real or personal property or of any claim
against the continued possession of any real property, whether owned or held under lease or sublease by the Company or the Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and its Subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights,
licenses, approvals, inventions, copyrights, domain names, technology, trade secrets, know-how (including unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property
and similar rights, including registrations and applications for registration thereof (collectively, &ldquo;<B>Intellectual Property
Rights</B>&rdquo;) necessary or material to the conduct of the business now conducted or proposed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus to be conducted by them, and the failure to own, possess or acquire such Intellectual
Property Rights and the expected expiration of any such Intellectual Property Rights would not, individually or in the aggregate,
have a Material Adverse Effect. To the Company&rsquo;s knowledge, none of the patents and patent applications owned or licensed
by the Company or its Subsidiaries is invalid or unenforceable, in whole or in part. To the Company&rsquo;s knowledge, none of
the Intellectual Property Rights owned or licensed by the Company or its Subsidiaries, other than patents and patent applications,
are invalid or unenforceable, in whole or in part. To the knowledge of the Company, there are no unreleased liens or security interests
which have been filed against any of the Intellectual Property Rights owned or licensed by the Company. Except as disclosed in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) the Company is not obligated to pay a material
royalty, grant a license or provide other material consideration to any third party in connection with the Intellectual Property
Rights owned by or licensed to the Company; (ii) to the Company&rsquo;s knowledge, there are no rights of third parties to any
of the Intellectual Property Rights owned by or licensed to the Company or its Subsidiaries, in any field of use, other than the
respective licensor to the Company of such Intellectual Property Rights; (iii) to the Company&rsquo;s knowledge, there is no material
infringement, misappropriation breach, default or other violation, or the occurrence of any event that with notice or the passage
of time would constitute any of the foregoing, by the Company or its Subsidiaries of any third party Intellectual Property Rights
or third parties of any of the Intellectual Property Rights of the Company or its Subsidiaries; (iv) there is no pending or, to
the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others against the Company or its Subsidiaries or,
to the Company&rsquo;s knowledge against any person or entity, (a) challenging the Company&rsquo;s or any of its Subsidiaries&rsquo;
rights in or to, or the violation of any of the terms of, any of their Intellectual Property Rights; (b) challenging the validity,
enforceability or scope of any such Intellectual Property Rights; or (c) that alleges the Company or any of its Subsidiaries infringes,
misappropriates or otherwise violates or conflicts with any Intellectual Property Rights or other proprietary rights of others,
and, in each case, the Company is unaware of any facts which would form a reasonable basis for any such claim; (v) none of the
Intellectual Property Rights owned by or licensed to the Company or its Subsidiaries in their businesses has been obtained or is
being used by the Company or its Subsidiaries in violation of any contractual obligation binding on the Company or any of its Subsidiaries
in violation of the rights of any persons; and (vi) to the Company&rsquo;s knowledge, no employee or consultant of the Company
or any of its Subsidiaries is in or has ever been in violation of any term of any employment or consulting contract, patent disclosure
agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any
restrictive covenant to or with a former employer or consultant where the basis of such violation relates to such employee&rsquo;s
employment with or such consultant&rsquo;s services to the Company or any of its Subsidiaries or actions undertaken by the employee
or consultant while employed with or providing services to the Company or any of its Subsidiaries. To the knowledge of the Company
and as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (1) neither the commercial
development nor the sale of any of the proposed products or processes of the Company, as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, infringes, misappropriates or otherwise violates, or would, upon the commercialization
of such proposed products or processes, infringe, misappropriate or otherwise violate, any Intellectual Property Rights of any
third party; and (2) each current and former employee and consultant of the Company (a) has executed an inventions assignment and
confidentiality agreement with the Company, on or about the respective date of hire, and signed copies of such agreements have
been made available to the Underwriters and their counsel; and (b) has signed or agreed to assign to the Company any and all Intellectual
Property Rights he or she may possess or may have possessed that are related to the Company&rsquo;s business, as currently conducted
and as proposed to be conducted, as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
All patents and patent applications owned by or licensed to the Company or under which the Company has rights have, to the knowledge
of the Company, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications
have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (the &ldquo;<B>USPTO</B>&rdquo;)
and any similar office or agency in the world in connection with such applications; and the Company is not aware of any facts required
to be disclosed to the USPTO or similar office or agency that were not disclosed and which would preclude the grant of a patent
in connection with any such application or would form the basis of a finding of invalidity with respect to any patents that have
issued with respect to such applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company&rsquo;s and the Subsidiaries&rsquo; information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, data (including the data of their respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of them), and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;)
are adequate for, and operate and perform in all material respects as required in connection with the operation of the business
of the Company and the Subsidiaries as currently conducted, and, to the Company&rsquo;s knowledge, are free from any material defects,
viruses, worms, Trojan horses or similar flaws or harmful programs.&nbsp; To the Company&rsquo;s knowledge, there has been no security
breach or attack or other compromise of or relating to any of the Company&rsquo;s or the Subsidiaries&rsquo; IT Systems, including
any such activity that would result in any unauthorized use, access, misappropriation or modification of Personal Data as defined
below.&nbsp; The Company and the Subsidiaries have been and are presently in material compliance with all applicable laws, statutes,
and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal or
external policies and contractual obligations relating to the privacy and security of IT Systems and data (including all personal,
personally identifiable, sensitive, confidential or regulated data (&ldquo;<B>Personal Data</B>&rdquo;)) and to the protection
of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Neither the Company nor any Subsidiary has been notified in writing, or have been required by applicable Law or by
any court or any other federal, state, local or foreign governmental or regulatory authority having jurisdiction over the Company,
the Subsidiaries or any of their properties or assets to notify in writing, any person of any Personal Data or security-related
incident. Neither the Company nor any Subsidiary has received any written notice of any claims, investigations, or alleged violations
of Law with respect to Personal Data. To the Company&rsquo;s knowledge, no person has commenced any proceedings relating to the
Company&rsquo;s or any Subsidiary&rsquo;s information privacy or data security practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and the Subsidiaries have implemented, and required of their third party vendors, adequate policies and
commercially reasonable security controls regarding the collection, use, disclosure, retention, confidentiality, integrity, and
availability of personal and business sensitive information in their possession, custody, or control, or held or processed on their
behalf, and regarding the integrity and availability of the information technology the Company and the Subsidiaries own, operate,
or outsource.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and the Subsidiaries maintain insurance in such amounts and covering such risks as the Company reasonably
considers adequate for the conduct of its business and the value of its properties and as is customary for companies engaged in
similar businesses in similar industries, all of which insurance is in full force and effect, except where the failure to maintain
such insurance would not reasonably be expected to have a Material Adverse Effect. There are no material claims by the Company
or the Subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under
a reservation of rights clause. The Company reasonably believes that it will be able to renew its existing insurance as and when
such coverage expires or will be able to obtain replacement insurance adequate for the conduct of the business and the value of
its properties at a cost that would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Except as would not reasonably be expected to result in a Material Adverse Effect, the Company and each Subsidiary
has accurately prepared and timely filed all federal, state, foreign and other tax returns that are required to be filed by it
or have been granted extensions thereof and has paid or made provision for the payment of all taxes, assessments, governmental
or other similar charges, including without limitation, all sales and use taxes and all taxes which the Company or any Subsidiary
is obligated to withhold from amounts owing to employees, creditors and third parties, with respect to the periods covered by such
tax returns (whether or not such amounts are shown as due on any tax return). Except as would not reasonably be expected to result
in a Material Adverse Effect, no deficiency assessment with respect to a proposed adjustment of the Company&rsquo;s or the Subsidiaries&rsquo;
federal, state, local or foreign taxes is pending or, to the Company&rsquo;s knowledge, threatened. The accruals and reserves on
the books and records of the Company and the Subsidiaries in respect of tax liabilities for any taxable period not finally determined
are adequate to meet any assessments and related liabilities for any such period and, since December&nbsp;31, 2019, except as would
not reasonably be expected to have a Material Adverse Effect, the Company and the Subsidiaries have not incurred any liability
for taxes other than in the ordinary course of its business. There is no tax lien, whether imposed by any federal, state, foreign
or other taxing authority, outstanding against the assets, properties or business of the Company or the Subsidiaries, other than
any such tax lien arising automatically under applicable law with respect to taxes not yet due and payable or being contested in
good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>No labor disturbance by the employees of the Company or the Subsidiaries exists or, to the Company&rsquo;s knowledge,
is imminent and the Company is not aware of any existing or imminent labor disturbances by the employees of any of its or the Subsidiaries&rsquo;
principal suppliers, manufacturers&rsquo;, customers or contractors, which, in either case (individually or in the aggregate),
would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect,
(i) each &ldquo;employee benefit plan&rdquo; (within the meaning of Section&nbsp;3(3) of the Employee Retirement Security Act of
1974, as amended (&ldquo;<B>ERISA</B>&rdquo;)) for which the Company or any member of its &ldquo;Controlled Group&rdquo; (defined
as any organization which is a member of a controlled group of corporations within the meaning of Section&nbsp;414 of the Internal
Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;)) would have any liability (each a &ldquo;<B>Plan</B>&rdquo;) has
been maintained in compliance with its terms and with the requirements of all applicable statutes, rules and regulations including
ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of
the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption;
(iii)&nbsp;with respect to each Plan subject to Title IV of ERISA (A)&nbsp;no &ldquo;reportable event&rdquo; (within the meaning
of Section&nbsp;4043(c) of ERISA) has occurred or is reasonably expected to occur, (B)&nbsp;no &ldquo;accumulated funding deficiency&rdquo;
(within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code), whether or not waived, has occurred or is reasonably
expected to occur, (C)&nbsp;the fair market value of the assets under each Plan exceeds the present value of all benefits accrued
under such Plan (determined based on those assumptions used to fund such Plan), and (D)&nbsp;neither the Company or any member
of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title IV of ERISA (other than contributions
to the Plan or premiums to the Pension Benefit Guaranty Corporation in the ordinary course and without default) in respect of a
Plan (including a &ldquo;multiemployer plan&rdquo;, within the meaning of Section&nbsp;4001(c)(3) of ERISA); and (iv)&nbsp;each
Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by
action or by failure to act, which would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(pp)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>There has been no storage, generation, transportation, handling, use, treatment, disposal, discharge, emission, contamination,
release or other activity involving any kind of hazardous, toxic or other wastes, pollutants, contaminants, petroleum products
or other hazardous or toxic substances, chemicals or materials (&ldquo;<B>Hazardous Substances</B>&rdquo;) by, due to, on behalf
of, or caused by the Company or the Subsidiaries (or, to the Company&rsquo;s knowledge, any other entity for whose acts or omissions
the Company is or may be liable) upon any property now or previously owned, operated, used or leased by the Company or the Subsidiaries,
or upon any other property, which would be a violation of or give rise to any liability under any applicable law, rule, regulation,
order, judgment, decree or permit, common law provision or other legally binding standard relating to pollution or protection of
human health and the environment (&ldquo;<B>Environmental Law</B>&rdquo;), except for violations and liabilities which, individually
or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. There has been no disposal, discharge,
emission, contamination or other release of any kind at, onto or from any such property or into the environment surrounding any
such property of any Hazardous Substances with respect to which the Company or any Subsidiary has knowledge, except as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary
has agreed to assume, undertake or provide indemnification for any liability of any other person under any Environmental Law, including
any obligation for cleanup or remedial action, except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. There is no pending or, to the Company&rsquo;s knowledge, threatened administrative, regulatory
or judicial action, claim or notice of noncompliance or violation, investigation or proceedings relating to any Environmental Law
against the Company or any Subsidiary, except in each case which, individually or in the aggregate, would not reasonably be expected
to have a Material Adverse Effect. No property of the Company or any Subsidiary is subject to any Lien under any Environmental
Law. Neither the Company nor any Subsidiary is subject to any order, decree, agreement or other individualized legal requirement
related to any Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(qq)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and the Subsidiaries (i)&nbsp;are in material compliance with all statutes, rules and regulations applicable
to the testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer
for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company or the
Subsidiaries (&ldquo;<B>Applicable Laws</B>&rdquo;) except where such noncompliance would not reasonably be expected to have a
Material Adverse Effect, (ii)&nbsp;have not received any Form 483 from the FDA, notice of adverse finding, warning letter, or other
written correspondence or notice from the FDA, the European Medicines Agency (the &ldquo;<B>EMA</B>&rdquo;), the U.K. Medicines
and Healthcare Products Regulatory Agency (the &ldquo;<B>MHRA</B>&rdquo;), the German <FONT STYLE="color: #333333; background-color: white">Federal
Institute for Drugs and Medical Devices (the &ldquo;<B>BfArM</B>&rdquo;),</FONT> or any other federal, state, local or foreign
governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates,
approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B>Authorizations</B>&rdquo;),
that would , individually or in the aggregate, result in a Material Adverse Effect; (iii)&nbsp;possess all material Authorizations
and such Authorizations are valid and in full force and effect and neither the Company nor any Subsidiary is in material violation
of any term of any such Authorizations except where such nonpossession, failure or noncompliance would not reasonably be expected
to have a Material Adverse Effect; (iv)&nbsp;have not received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from the FDA, the EMA, the MHRA, the BfArM, or any other federal, state,
local or foreign governmental or regulatory authority or third party alleging that any Company product, operation or activity is
in material violation of any Applicable Laws or Authorizations which noncompliance would reasonably be expected to have a Material
Adverse Effect and has no knowledge that the FDA, the EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental
or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding
against the Company; (v)&nbsp;have not received written notice that the FDA, EMA, the MHRA, the BfArM, or any other federal, state,
local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify
or revoke any material Authorizations that would reasonably be expected to have a Material Adverse Effect and has no knowledge
that the FDA, EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority is considering
such action; and (vi)&nbsp;have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations, except whether
the failure to file, obtain, maintain or submit such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments would not result in a Material Adverse Effect, and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed
(or were corrected or supplemented by a subsequent submission) except such incompletions and incorrections as would not reasonably
be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(rr)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company and each of its Subsidiaries has operated and currently is in compliance in all material respects with
all applicable Health Care Laws (as defined below), including, without limitation, the rules and regulations of the FDA, the U.S.
Department of Health and Human Services Office of Inspector General, the Centers for Medicare &amp; Medicaid Services, the Office
for Civil Rights, the Department of Justice or any other governmental agency or body having jurisdiction over the Company or any
of its activities, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties,
or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes of
this Agreement, &ldquo;Health Care Laws&rdquo; shall mean the federal Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the
Physician Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h), the civil False Claims Act (31 U.S.C. &sect;&sect; 3729 et seq.), the
criminal False Claims Act (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including
but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the Health Insurance Portability
and Accountability Act of 1996 (42 U.S.C. &sect; 1320d et seq.) (&ldquo;<B>HIPAA</B>&rdquo;), the exclusion laws (42 U.S.C. &sect;
1320a-7), the civil monetary penalties law (42 U.S.C. &sect; 1320a-7a), HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act (42 U.S.C. &sect;&sect; 17921 et seq.), the patient privacy, data security and breach notification
provisions under HIPAA, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.), the Public Health Service
Act (42 U.S.C. &sect;&sect; 262 et seq.), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social
Security Act), the regulations promulgated pursuant to such laws, and any other similar local, state or federal law and regulations.
The Company has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence,
communication or notice from the FDA or any other governmental or regulatory authority alleging or asserting noncompliance with
any Health Care Laws applicable to the Company. The Company is not a party to nor has any ongoing reporting obligations pursuant
to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders,
plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Neither the Company, its
Subsidiaries nor any of their respective employees, officers, directors or, to the Company&rsquo;s knowledge, consultants has been
excluded, suspended or debarred from participation in any U.S. state or federal health care program or human clinical research
or, to the Company&rsquo;s knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action
that would reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(ss)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>All medical devices and related technology currently being development by, on behalf of or sponsored by the Company
or its Subsidiaries, to the Company&rsquo;s knowledge, are being, conducted in all material respects in accordance with standard
medical and scientific research procedures and with all applicable local, state and federal laws, rules and regulations, including,
without limitation, the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations at 21 C.F.R. Parts 50,
54, 56, 58 and 312; the descriptions of the developments and resulting technology and devices contained in the Registration Statement,
the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the data
derived from the use of such technology and devices; the Company is not aware of any developments, the results of which are inconsistent
with or otherwise call into question the developments described or referred to in the Registration Statement, the Pricing Disclosure
Package or the Prospectus; and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge
of the Company, threatened to initiate, any action to place a hold order on, or otherwise terminate, delay or suspend, any proposed
or ongoing developments or implementation of such technology conducted or proposed to be conducted by or on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(tt)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company has established and administers a compliance program applicable to the Company, to assist the Company
and the directors, officers and employees of the Company in complying with applicable regulatory guidelines (including, without
limitation, those administered by the FDA, the EMA, the MHRA, the BfArM, and any other foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA or EMA); except where such noncompliance would
not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(uu)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee,
affiliate or other person acting on behalf of the Company or any Subsidiary, has authorized the giving of, offer or promise to
give or (i)&nbsp;made any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity;
(ii)&nbsp;made any direct or indirect unlawful payment to any domestic governmental official, &ldquo;foreign official&rdquo; (as
defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively,
the &ldquo;<B>FCPA</B>&rdquo;)) or employee; (iii)&nbsp;violated or is in violation of any provision of the FCPA, UK Bribery Act,
any applicable non-U.S. anti-bribery statute or regulation or any locally applicable corruption laws; (iv)&nbsp;made any bribe,
rebate, payoff, influence payment, kickback or other unlawful payment; or (v)&nbsp;received notice of any investigation, proceeding
or inquiry by any governmental agency, authority or body regarding any of the matters in clauses (i)-(iv) above; and the Company
and the Subsidiaries and, to the Company&rsquo;s knowledge, the Company&rsquo;s affiliates have conducted their respective businesses
in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably
expected to continue to ensure, continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(vv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting
and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT
Act) (Title III of Pub. L. 107-56 (signed into law October&nbsp;26, 2001)) (the &ldquo;<B>USA Patriot Act</B>&rdquo;), and those
of the Currency and Foreign Transactions Reporting Act of 1970, as amended, and the money laundering statutes of all applicable
jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered
or enforced by any governmental agency (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or the Subsidiaries with
respect to the Money Laundering Laws is pending or, to the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(ww)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>None of the Company nor any Subsidiary nor, to the knowledge of the Company, any officer, director, agent, employee,
affiliate or any person acting on behalf of the Company or any Subsidiary is or, in the past five years, has been (A)&nbsp;engaged
in any services (including financial services), transfers of goods, software, or technology, or any other business activity related
to (i)&nbsp;Cuba, Iran, North Korea, Sudan, Syria or the Crimea region of Ukraine claimed by Russia (&ldquo;<B>Sanctioned Countries</B>&rdquo;),
(ii) the government of any Sanctioned Country, (iii)&nbsp;any person, entity or organization located in, resident in, formed under
the laws of, or owned or controlled by the government of, any Sanctioned Country, or (iv)&nbsp;any person, entity or organization
made subject or target of any sanctions administered or enforced by the United States Government (including the US Department of
Treasury, Office of Foreign Assets Control and the US Department of State), including, without limitation, the list of Specially
Designated Nationals (&ldquo;<B>SDN List</B>&rdquo;) of the Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<B>OFAC</B>&rdquo;),
or by the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury-UK, or other relevant sanctions authority
(collectively, &ldquo;<B>Sanctions</B>&rdquo;) and the Company will not directly or indirectly use the proceeds of this offering,
or lend, contribute or otherwise make available such proceeds to any of its Subsidiaries, or any joint venture partner or other
person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that
currently is the subject to any U.S. sanctions administered by OFAC or in any other manner that will result in a violation by any
person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of U.S. sanctions
administered by OFAC; (B)&nbsp;engaged in any transfers of goods, technologies or services (including financial services) that
may assist the governments of Sanctioned Countries or facilitate money laundering or other activities proscribed by United States
laws, rules or regulations; (C)&nbsp;is a person, entity or organization currently the subject of any Sanctions; or (D)&nbsp;located,
organized or resident in any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company (i) does not have any material lending or other relationship with any bank or lending affiliate of any
Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Shares to repay any outstanding debt owed
to any affiliate of any Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate signed by an officer of
the Company and delivered to the Representative or to counsel for the Underwriters shall be deemed to be a representation and warranty
by the Company to each Underwriter as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Purchase, Sale and Delivery of the Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>On the basis of the representations, warranties, covenants and agreements herein contained, and subject to the terms
and conditions herein set forth, the Company agrees to sell to each Underwriter and each Underwriter, severally and not jointly,
agrees to purchase from the Company, at a purchase price per share of $16.92, the number of Firm Shares set forth opposite their
respective names on <U>Schedule I</U> hereto together with any additional number of Shares which such Underwriter may become obligated
to purchase pursuant to the provisions of Section&nbsp;10 hereof, subject, however, to such adjustments to eliminate fractional
shares as the Representative in its sole discretion shall make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The closing of the issuance of the Firm Shares shall be held at the office of Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C. (&ldquo;<B>Underwriters&rsquo; Counsel</B>&rdquo;), or at such other place as shall be agreed upon by the Representative
and the Company, at 10:00 a.m., New York City time, on March 5, 2021, or such other time and date as the Representative and the
Company may agree upon in writing (such time and date of payment and delivery being herein called the &ldquo;<B>Closing Date</B>&rdquo;).
Payment of the purchase price for the Firm Shares shall be made by wire transfer in same day funds to the accounts specified by
the Company upon delivery of the Firm Shares to the Representative through the facilities of The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)
for the respective accounts of the several Underwriters. The Firm Shares shall be registered in such name or names and shall be
in such denominations as the Representative may request in writing not later than the business day immediately prior to the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>In addition, the Company hereby grants to the Underwriters the option to purchase up to 171,516 Additional Shares
at the same purchase price per share to be paid by the Underwriters for the Firm Shares as set forth in Section&nbsp;2(a) above.
This option may be exercised at any time and from time to time, in whole or in part on one or more occasions, on or before the
thirtieth day following the date of the Prospectus, by written notice from the Representative to the Company. Such notice shall
set forth the aggregate number of Additional Shares as to which the option is being exercised and the date and time, as reasonably
determined by the Representative, when the Additional Shares are to be delivered (any such date and time being herein sometimes
referred to as an &ldquo;<B>Additional Closing Date</B>&rdquo;); <I>provided</I>, <I>however</I>, that no Additional Closing Date
shall occur earlier than the Closing Date or earlier than the second full business day after the date on which the option shall
have been exercised nor later than the eighth full business day after the date on which the option shall have been exercised. On
the basis of the representations, warranties, covenants and agreements herein contained, but subject to the terms and conditions
herein set forth, upon any exercise of the option as to all or any portion of the Additional Shares, each Underwriter, acting severally
and not jointly, agrees to purchase from the Company the number of Additional Shares that bears the same proportion of the total
number of Additional Shares then being purchased as the number of Firm Shares set forth opposite the name of such Underwriter in
<U>Schedule I</U> hereto (or such number increased as set forth in Section&nbsp;10 hereof) bears to the total number of Firm Shares
that the Underwriters have agreed to purchase hereunder, subject, however, to such adjustments to eliminate fractional shares as
the Representative in its sole discretion shall make. In the event that the Underwriters exercise less than their full option to
purchase Additional Shares, the number of Additional Shares to be sold by the Company shall be, as nearly as practicable, in the
same proportion as the maximum number of Additional Shares to be sold by the Company and the number of Additional Shares to be
sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The closing of the issuance of the Additional Shares shall be held at the office of Underwriters&rsquo; Counsel,
or at such other place as shall be agreed upon by the Representative and the Company, at 10:00 a.m., New York City time, on any
Additional Closing Date, or such other time as shall be agreed upon by the Representative and the Company. Payment of the purchase
price for the Additional Shares shall be made by wire transfer in same day funds to the account specified by the Company upon delivery
of the Additional Shares to the Representative through the facilities of DTC for the respective accounts of the several Underwriters.
The Additional Shares shall be registered in such name or names and shall be in such denominations as the Representative may request
in writing not later than the business day immediately prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Offering</U>. Upon authorization of the release of the Firm Shares by the Representative, the Underwriters propose
to offer the Shares for sale to the public upon the terms and conditions set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Covenants of the Company</U>. In addition to the other covenants and agreements of the Company contained herein,
the Company further covenants and agrees with each of the Underwriters that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company shall prepare the Prospectus in a form approved by the Representative and file such Prospectus pursuant
to, and within the time period specified in, Rule 424(b) and Rule 430B under the Securities Act; prior to the last date on which
an Additional Closing Date, if any, may occur, the Company shall file no further amendment to the Registration Statement or amendment
or supplement to the Prospectus to which the Representative objects in writing after being furnished in advance a copy thereof
and given a reasonable opportunity to review and comment thereon; the Company shall notify the Representative promptly (and, if
requested by the Representative, confirm such notice in writing)&nbsp;(i) when the Registration Statement and any amendments thereto
become effective, (ii)&nbsp;of any request by the Commission for any amendment of or supplement to the Registration Statement or
the Prospectus, including any document incorporated by reference therein or for any additional information, (iii)&nbsp;of the Company&rsquo;s
intention to file, or prepare any supplement or amendment to, the Registration Statement, any Preliminary Prospectus or the Prospectus,
(iv)&nbsp;of the mailing or the delivery to the Commission for filing of any amendment of or supplement to the Registration Statement
or the Prospectus, including but not limited to Rule 462(b) under the Securities Act, (v)&nbsp;of the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, or suspending
the use of any Preliminary Prospectus or the Prospectus or, in each case, of the initiation or threatening of any proceedings therefore,
(vi)&nbsp;of the receipt of any comments from the Commission, and (vii)&nbsp;of the receipt by the Company of any notification
with respect to the suspension of the qualification of the Shares for sale in any jurisdiction or the initiation or threatening
of any proceeding for that purpose. If the Commission shall propose or enter a stop order at any time, the Company will make every
reasonable effort to prevent the issuance of any such stop order and, if issued, to obtain the lifting of such order as soon as
possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If at any time when a prospectus relating to the Shares (or, in lieu thereof, the notice referred to in Rule 173(a)
under the Securities Act) is required to be delivered under the Securities Act, any event shall have occurred as a result of which
the Pricing Disclosure Package (prior to the availability of the Prospectus) or the Prospectus as then amended or supplemented
would, in the judgment of the Underwriters or the Company, include an untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances existing at the time of delivery
of such Pricing Disclosure Package or Prospectus (or, in lieu thereof, the notice referred to in Rule 173(a) under the Securities
Act) to the purchaser, not misleading, or if to comply with the Securities Act, the Exchange Act or the Rules and Regulations it
shall be necessary at any time to amend or supplement the Pricing Disclosure Package, the Prospectus or the Registration Statement,
or to file any document incorporated by reference in the Registration Statement or the Prospectus or in any amendment thereof or
supplement thereto, the Company will notify the Representative promptly and prepare and file with the Commission an appropriate
amendment, supplement or document (in form and substance satisfactory to the Representative) that will correct such statement or
omission or effect such compliance, and will use its reasonable best efforts to have any amendment to the Registration Statement
declared effective as soon as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company will not, without the prior consent of the Representative, (i)&nbsp;make any offer relating to the Shares
that would constitute a &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under the Securities Act, except for any Issuer
Free Writing Prospectus set forth in <U>Schedule II</U> hereto and any electronic Road Show previously approved by the Representative,
or (ii)&nbsp;file, refer to, approve, use or authorize the use of any &ldquo;free writing prospectus&rdquo; as defined in Rule
405 under the Securities Act with respect to the Offering or the Shares. If at any time any event shall have occurred as a result
of which any Issuer Free Writing Prospectus as then amended or supplemented would, in the judgment of the Underwriters or the Company,
conflict with the information in the Registration Statement, the Pricing Disclosure Package or the Prospectus as then amended or
supplemented or would, in the judgment of the Underwriters or the Company, include an untrue statement of a material fact or omit
to state any material necessary in order to make the statements therein, in the light of the circumstances existing at the time
of delivery to the purchaser, not misleading, or if to comply with the Securities Act or the Rules and Regulations it shall be
necessary at any time to amend or supplement any Issuer Free Writing Prospectus, the Company will notify the Representative promptly
and, if requested by the Representative, prepare and furnish without charge to each Underwriter an appropriate amendment or supplement
(in form and substance satisfactory to the Representative) that will correct such statement, omission or conflict or effect such
compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company will comply with the requirements of Rule 433 with respect to each Issuer Free Writing Prospectus including,
without limitation, all prospectus delivery, filing, record retention and legending requirements applicable to each such Issuer
Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the request of the Representative, the Company will promptly deliver to each of the Representative and Underwriters&rsquo;
Counsel a signed copy of the Registration Statement, as initially filed and all amendments thereto, including all consents and
exhibits filed therewith. At the request of the Representative, the Company will promptly deliver to each of the Underwriters such
number of copies of any Preliminary Prospectus, the Prospectus, the Registration Statement, all amendments of and supplements to
such documents, if any, and all documents incorporated by reference in the Registration Statement and Prospectus or any amendment
thereof or supplement thereto, as the Representative may reasonably request. Prior to 10:00 A.M., New York City time, on the business
day next succeeding the date of this Agreement and from time to time thereafter, at the request of the Representative, the Company
will furnish the Underwriters with copies of the Prospectus in New York City in such quantities as the Representative may reasonably
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Promptly from time to time, the Company will use its reasonable best efforts, in cooperation with the Representative,
to qualify the Shares for offering and sale under the securities laws relating to the offering or sale of the Shares of such jurisdictions,
domestic or foreign, as the Representative may reasonably request and to maintain such qualification in effect for so long as required
for the distribution thereof; except that in no event shall the Company be obligated in connection therewith (i) to qualify as
a foreign corporation, (ii) to execute a general consent to service of process or (iii) subject itself to taxation in any jurisdiction
where it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company will make generally available to its security holders and to the Representative as soon as practicable
an earnings statement of the Company and the Subsidiaries (which need not be audited) covering a period of at least twelve months
beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions
of Section&nbsp;11(a) of the Securities Act and the Rules and Regulations (including, at the option of the Company, Rule 158).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During period of 90 days from the date of the Prospectus (the &ldquo;<B>Lock-Up Period</B>&rdquo;), without the prior written
consent of Guggenheim Securities, the Company (i)&nbsp;will not, directly or indirectly, issue, offer, sell, agree to issue, offer
or sell, solicit offers to purchase, grant any call option, warrant or other right to purchase, purchase any put option or other
right to sell, pledge, borrow or otherwise dispose of any shares of Common Stock or any securities convertible into or exercisable
or exchangeable for Common Stock, or make any public announcement of any of the foregoing, (ii)&nbsp;will not establish or increase
any &ldquo;put equivalent position&rdquo; or liquidate or decrease any &ldquo;call equivalent position&rdquo; (in each case within
the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations thereunder) with respect to any shares of Common
Stock or any securities convertible into or exercisable or exchangeable for Common Stock, and (iii)&nbsp;will not otherwise enter
into any swap, derivative or other transaction or arrangement that transfers to another, in whole or in part, any economic consequence
of ownership of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock,
whether or not such transaction is to be settled by delivery of any shares of Common Stock, securities convertible into or exercisable
or exchangeable for Common Stock, other securities, cash or other consideration, other than (A) the Shares to be sold hereunder,
(B)&nbsp;upon the exercise of an option or warrant, the vesting of restricted stock or restricted stock units, performance stock
units or deferred stock units or the conversion or exchange of a security outstanding on the date hereof as referred to in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, (C)&nbsp;pursuant to the stock-based compensation plans
of the Company and the Subsidiaries as referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
(including any amendments to such plans and the 2019 Equity Stock Purchase Plan, as amended), (D) pursuant to an inducement award
permitted to be issued without shareholder approval by Nasdaq rules, (E) shares of Common Stock or other securities issued to a
third party in connection with a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements,
collaboration agreements or intellectual property license agreements) or any bona fide acquisition of assets of not less than a
majority or controlling portion of the equity of another entity, provided that (x) any such issuance is not primarily for the purpose
of raising capital; (y) the aggregate number of shares of Common Stock that the Company may sell or issue or agree to sell or issue
shall not exceed 5% of the total number of shares of Common Stock issued and outstanding as of the date of this Agreement and (z)
each recipient of shares of Common Stock or securities convertible into or exercisable for Common Stock shall execute a lock-up
agreement substantially in the form of Exhibit B hereto, (F) the filing of any registration statement on Form S-8 or a successor
form thereto relating to the shares of Common Stock granted pursuant to or reserved for issuance under the stock-based compensation
plans of the Company and the Subsidiary referred to in clause (C), and (G) the filing of any shelf registration statement on Form
S-3 or a successor form thereto, provided that no sales of the Company&rsquo;s securities shall be made under any registration
statement or agreement referred to in clause (G).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>[Reserved.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>During the period of two years from the Effective Date of the Registration Statement, the Company will furnish to
the Representative copies of all reports or other communications (financial or other) furnished to security holders or from time
to time published or publicly disseminated by the Company, and will deliver to the Representative as soon as they are available,
copies of any reports, financial statements and proxy or information statements furnished to or filed with the Commission or any
national securities exchange on which any class of securities of the Company is listed; provided, that the Company will be deemed
to have furnished such reports, other communications, financial statements and proxy or information statements to the Representative
to the extent they are filed on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company will use its best efforts to maintain the listing of its Common Stock (including the Shares) on The Nasdaq Capital
Market (or another Nasdaq market) following the issuance of the Shares pursuant to this Agreement provided; however that this covenant
shall not prevent a sale, merger or similar transaction involving the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company will apply the net proceeds from the sale of the Shares as set forth under the caption &ldquo;Use of
Proceeds&rdquo; in the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company, during the period when a prospectus (or, in lieu thereof, the notice referred to in Rule 173(a) under
the Securities Act) is required to be delivered under the Securities Act in connection with the offer or sale of the Shares, will
file all reports and other documents required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c),
14 or 15(d) of the Exchange Act and the Rules and Regulations within the time periods required thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If the Company elects to rely upon Rule 462(b) under the Securities Act, the Company shall file a Rule 462(b) Registration
Statement with the Commission in compliance with Rule 462(b) by 10:00 p.m. (New York City time), on the date of this Agreement,
and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement
or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company will not take, and will cause its affiliates (within the meaning of Rule 144 under the Securities Act)
not to take, directly or indirectly, any action which constitutes or is designed to cause or result in, or which would reasonably
be expected to constitute, cause or result in, the stabilization or manipulation of the price of any security to facilitate the
sale or resale of the Shares or to result in a violation of Regulation M under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company will do and perform all things required or necessary to be done and performed under this Agreement by
it prior to each Closing Date, and to satisfy all conditions precedent to the Underwriters&rsquo; obligations hereunder to purchase
the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Covenant of the Underwriters</U>. Each Underwriter, severally and not jointly, covenants and agrees with the Company
that such Underwriter will not use or refer to any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 under the Securities
Act) without the prior written consent of the Company if such Underwriter&rsquo;s use of or reference to such &ldquo;free writing
prospectus&rdquo; would require the Company to file with the Commission any &ldquo;issuer information&rdquo; (as defined in Rule
433 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Payment of Expenses</U>. Whether or not the transactions contemplated by this Agreement, the Registration Statement
and the Prospectus are consummated or this Agreement is terminated (provided, however, the Company shall have no obligation to
reimburse any defaulting Underwriter pursuant to Section 10 herewith), the Company hereby agrees to pay all costs and expenses
incident to the performance of its obligations hereunder, including the following: (i)&nbsp;all expenses in connection with the
preparation, printing and filing of the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus,
the Prospectus and any and all amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters
and dealers; (ii)&nbsp;the reasonable and documented fees, disbursements and expenses of the Company&rsquo;s counsel and accountants
in connection with the registration of the Shares under the Securities Act and the Offering; (iii)&nbsp;the cost of producing this
Agreement and any agreement among Underwriters, blue sky survey, closing documents and other instruments, agreements or documents
(including any compilations thereof) in connection with the Offering; (iv)&nbsp;all expenses in connection with the qualification
of the Shares for offering and sale under state or foreign securities or blue sky laws as provided in Section&nbsp;4(g) hereof,
including the reasonable and documented fees and disbursements of counsel for the Underwriters in connection with such qualification
or offering and in connection with any blue sky survey; (v)&nbsp;all fees and expenses in connection with listing the Shares on
Nasdaq and with any filings required to be made with FINRA; (vi)&nbsp;the costs and expenses of the Company relating to investor
presentations on any Road Show undertaken in connection with the marketing of the Shares, including without limitation, expenses
associated with the production and distribution (including electronic) of Road Show slides and graphics, fees and expenses of any
consultants engaged in connection with the Road Show presentations, travel and lodging expenses of the representatives and officers
of the Company in connection with the Road Show; (vii)&nbsp;any stock transfer taxes incurred in connection with this Agreement
or the Offering; and (viii) the fees and expenses incident to the performance of the obligations of the Representative (including
reasonable and documented fees, disbursements and expenses of counsel for the Underwriters) in an amount not to exceed $125,000
without the Company&rsquo;s consent, not to be unreasonably withheld, not including any fees, disbursements and expenses in (v)
above. The Company also will pay or cause to be paid: (x)&nbsp;the cost of preparing stock certificates representing the Shares;
(y)&nbsp;the cost and charges of any transfer agent or registrar for the Shares; and (z) all other reasonable costs and expenses
incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Conditions of Underwriters&rsquo; Obligations</U>. The several obligations of the Underwriters to purchase and
pay for the Firm Shares and the Additional Shares, as provided herein, shall be subject to the accuracy of the representations
and warranties of the Company herein contained, as of the date hereof and as of the applicable Closing Date (for purposes of this
Section&nbsp;7, &ldquo;<B>Closing Date</B>&rdquo; shall refer to the Closing Date for the Firm Shares and any Additional Closing
Date, if different, for the Additional Shares), to the performance by the Company of all of its obligations hereunder, and to each
of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Prospectus shall have been filed with the Commission in a timely fashion in accordance with Section&nbsp;4(a)
hereof; no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, and no
stop order suspending or preventing the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus, or the Prospectus,
shall have been issued by the Commission and no proceedings therefor shall have been initiated or threatened by the Commission;
all requests for additional information on the part of the Commission shall have been complied with to the Representative&rsquo;s
reasonable satisfaction; if the Company has elected to rely on Rule 462(b) under the Securities Act, the Rule 462(b) Registration
Statement shall have become effective by 10:00 p.m. (New York City time) on the date of this Agreement; and all necessary regulatory
or stock exchange approvals shall have been received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the Closing Date the Representative shall have received the written opinion and negative assurance statement of
Dentons US, LLP, counsel for the Company, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably
satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the Closing Date the Representative shall have received the written opinion of Loginov IP, intellectual property
counsel for the Company, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory
to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the Closing Date, the Representative shall have received the written opinion and negative assurance statement
of Underwriters&rsquo; Counsel, dated the Closing Date and addressed to the Underwriters, in form and substance satisfactory to
the Representative, with respect to the issuance and sale of the Shares, the Registration Statement, the Pricing Disclosure Package,
the Prospectus and such other matters as the Representative may require, and the Company shall have furnished to Underwriters&rsquo;
Counsel such documents as they may reasonably request for the purpose of enabling them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the Closing Date the Representative shall have received a certificate of the Chief Executive Officer and Chief
Financial Officer of the Company, dated the Closing Date, in form and substance satisfactory to the Representative as to the accuracy
of the representations and warranties of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the Closing
Date, as to the performance by the Company of all of its obligations hereunder to be performed at or prior to the Closing Date,
as to the matters set forth in subsections (a)&nbsp;and (h) of this Section&nbsp;7, and as to such other matters as the Representative
may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the time this Agreement is executed and at the Closing Date, the Representative shall have received a comfort
letter, from BDO USA, LLP, independent registered public auditing firm for the Company, dated, respectively, as of the date of
this Agreement and as of the Closing Date, addressed to the Underwriters and in form and substance satisfactory to the Underwriters
and Underwriters&rsquo; Counsel, containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort
letters&rdquo; to underwriters with respect to the financial statements and certain financial information contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the time this Agreement is executed and at the Closing Date, the Representative shall have received a certificate
of the Chief Financial Officer, dated, respectively, as of the date of this Agreement and as of the Closing Date, addressed to
the Underwriters and in form and substance satisfactory to the Underwriters and Underwriters&rsquo; Counsel, with respect to certain
financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Neither the Company nor any Subsidiary shall have sustained, since the date of the latest audited financial statements
included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, any material
loss or interference with its business or properties from fire, explosion, flood, earthquake, hurricane, accident or other calamity,
whether or not covered by insurance, or from any labor dispute or any legal or governmental proceeding, other than as set forth
in the Registration Statement, the Pricing Disclosure Package and the Prospectus (exclusive of any supplement thereto); and (ii)&nbsp;subsequent
to the dates as of which information is given in the Registration Statement (exclusive of any amendment thereto subsequent to the
date hereof) and the Pricing Disclosure Package and the Prospectus (exclusive of any supplement thereto), there shall not have
been any change in the capital stock or long-term or short-term debt of the Company or the Subsidiaries or any change or any development
involving a change, whether or not arising from transactions in the ordinary course of business, in the business, general affairs,
management, condition (financial or otherwise), results of operations, stockholders&rsquo; equity, properties or prospects of the
Company and the Subsidiaries, individually or taken as a whole, the effect of which, in any such case described above, is, in the
judgment of the Representative, so material and adverse as to make it impracticable or inadvisable to proceed with the Offering
on the terms and in the manner contemplated in the Registration Statement, the Pricing Disclosure Package and the Prospectus (exclusive
of any such supplement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>No Underwriter shall have discovered and disclosed to the Company on or prior to such Closing Date that any of the
Registration Statement, the Pricing Disclosure Package or the Prospectus, or any amendment or supplement thereto, contains an untrue
statement of a fact which, in the opinion of Underwriters&rsquo; Counsel, is material or omits to state a fact which, in the opinion
of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>As of the date of this Agreement, the Representative shall have received a duly executed lock-up agreement substantially
in the form of Exhibit B hereto (a &ldquo;<B>Lock-Up Agreement</B>&rdquo;) from each person who is a director or executive officer
of the Company listed on <U>Schedule IV</U> hereto, in each case substantially in the form attached hereto as <U>Exhibit B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>At the Closing Date, the Shares shall have been approved for listing on The Nasdaq Capital Market, subject only to
official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If a filing has been made with FINRA, FINRA shall have confirmed that it has not raised any objection with respect
to the fairness and reasonableness of the underwriting terms and arrangements relating to the Offering of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company shall have furnished the Underwriters and Underwriters&rsquo; Counsel with such other certificates, opinions
or other documents as they may have reasonably requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the conditions specified in this
Section&nbsp;7 shall not have been fulfilled when and as required by this Agreement, or if any of the certificates, opinions, written
statements or letters furnished to the Representative or to Underwriters&rsquo; Counsel pursuant to this Section&nbsp;7 shall not
be satisfactory in form and substance to the Representative and to Underwriters&rsquo; Counsel, all obligations of the Underwriters
hereunder may be cancelled by the Representative at, or at any time prior to, the Closing Date and the obligations of the Underwriters
to purchase the Additional Shares may be cancelled by the Representative at, or at any time prior to, any Additional Closing Date.
Notice of such cancellation shall be given to the Company in writing or by telephone. Any such telephone notice shall be confirmed
promptly thereafter in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company shall indemnify and hold harmless each Underwriter, its affiliates, directors, officers, employees and
each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act, against any and all losses, liabilities, claims, damages and expenses whatsoever as incurred (including but
not limited to attorneys&rsquo; fees and any and all expenses whatsoever incurred in investigating, preparing or defending against
any litigation, commenced or threatened, or any claim whatsoever, and any and all amounts paid in settlement of any claim or litigation),
joint or several, to which they or any of them may become subject under the Securities Act, the Exchange Act or otherwise, insofar
as such losses, liabilities, claims, damages or expenses (or actions in respect thereof) arise out of or are based upon (i)&nbsp;any
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included (A)&nbsp;in any
Preliminary Prospectus or the Prospectus, or in any supplement thereto or amendment thereof, or in any Issuer Free Writing Prospectus,
or in any &ldquo;issuer information&rdquo; (as defined in Rule 433(h)(2) under the Securities Act) filed or required to be filed
pursuant to Rule 433(d) under the Securities Act, or (B)&nbsp;in any other materials or information provided to investors by, or
with the approval of, the Company in connection with the Offering, including in any Road Show for the Offering (&ldquo;<B>Marketing&nbsp;Materials</B>&rdquo;),
or the omission or alleged omission to state in any Preliminary Prospectus or the Prospectus, or in any supplement thereto or amendment
thereof, or in any Issuer Free Writing Prospectus, or in any &ldquo;issuer information&rdquo; (as defined in Rule 433(h)(2) under
the Securities Act) filed or required to be filed pursuant to Rule 433(d) under the Securities Act, or in any Marketing Materials,
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; provided, however, that the Company will not be liable in any such case to the extent but only to the extent that
any such loss, liability, claim, damage or expense arises out of or is based upon any such untrue statement or alleged untrue statement
or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company
by or on behalf of any Underwriter through the Representative expressly for use therein. The parties agree that such information
provided by or on behalf of any Underwriter through the Representative consists solely of the material referred to in Section&nbsp;19
hereof. This indemnity agreement will be in addition to any liability which the Company may otherwise have, including but not limited
to other liability under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Each Underwriter, severally and not jointly, shall indemnify and hold harmless the Company, each of the directors
of the Company, each of the officers of the Company who shall have signed the Registration Statement, and each other person, if
any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act,
against any losses, liabilities, claims, damages and expenses whatsoever as incurred (including but not limited to attorneys&rsquo;
fees and any and all expenses whatsoever incurred in investigating, preparing or defending against any litigation, commenced or
threatened, or any claim whatsoever, and any and all amounts paid in settlement of any claim or litigation), joint or several,
to which they or any of them may become subject under the Securities Act, the Exchange Act or otherwise, insofar as such losses,
liabilities, claims, damages or expenses (or actions in respect thereof) arise out of or are based upon (i)&nbsp;any untrue statement
or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or the omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein
not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any related Preliminary
Prospectus or the Prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission
or alleged omission to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, in each case to the extent, but only to the extent, that any such loss, liability,
claim, damage or expense arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged
omission made therein in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of
any Underwriter through the Representative specifically for use therein; provided, however, that in no case shall any Underwriter
be liable or responsible for any amount in excess of the underwriting discount applicable to the Shares to be purchased by such
Underwriter hereunder. The parties agree that such information provided by or on behalf of any Underwriter through the Representative
consists solely of the material referred to in Section&nbsp;19 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Promptly after receipt by an indemnified party under subsection (a)&nbsp;or (b) above of notice of any claims or
the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying
party under such subsection, notify each party against whom indemnification is to be sought in writing of the claim or the commencement
thereof (but the failure so to notify an indemnifying party shall not relieve the indemnifying party from any liability which it
may have under this Section&nbsp;8 to the extent that it is not materially prejudiced as a result thereof or otherwise has notice
of any such action, and in any event shall not relieve it from any liability that such indemnifying party may have otherwise than
on account of the indemnity agreement hereunder). In case any such claim or action is brought against any indemnified party, and
it notifies an indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate, at its own
expense in the defense of such action, and to the extent it may elect by written notice delivered to the indemnified party promptly
after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel satisfactory to such
indemnified party; provided however, that counsel to the indemnifying party shall not (except with the written consent of the indemnified
party) also be counsel to the indemnified party. Notwithstanding the foregoing, the indemnified party or parties shall have the
right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of
such indemnified party or parties unless (i)&nbsp;the employment of such counsel shall have been authorized in writing by one of
the indemnifying parties in connection with the defense of such action, (ii)&nbsp;the indemnifying parties shall not have employed
counsel to have charge of the defense of such action within a reasonable time after notice of commencement of the action, (iii)&nbsp;the
indemnifying party does not diligently defend the action after assumption of the defense, or (iv)&nbsp;such indemnified party or
parties shall have reasonably concluded that there may be defenses available to it or them which are different from or additional
to those available to one or all of the indemnifying parties (in which case the indemnifying parties shall not have the right to
direct the defense of such action on behalf of the indemnified party or parties), in any of which events such fees and expenses
shall be borne by the indemnifying parties hereof, then, in addition to the fees and expenses of such counsel for the indemnified
parties, the indemnifying party shall be liable for the reasonable fees and expenses of not more than one counsel (in addition
to any local counsel) separate from its own counsel. No indemnifying party shall, without the prior written consent of the indemnified
parties, effect any settlement or compromise of, or consent to the entry of judgment with respect to, any pending or threatened
claim, investigation, action or proceeding in respect of which indemnity or contribution may be or would have been sought by an
indemnified party under this Section&nbsp;8 or Section&nbsp;9 hereof (whether or not the indemnified party is an actual or potential
party thereto), unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release of the indemnified party
from all liability arising out of such claim, investigation, action or proceeding and (ii)&nbsp;does not include a statement as
to or an admission of fault, culpability or any failure to act, by or on behalf of the indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Contribution</U>. In order to provide for contribution in circumstances in which the indemnification provided
for in Section&nbsp;8 hereof is for any reason held to be unavailable from any indemnifying party or is insufficient to hold harmless
a party indemnified thereunder, the Company and the Underwriters severally shall contribute to the aggregate losses, claims, damages,
liabilities and expenses of the nature contemplated by such indemnification provision (including any investigation, legal and other
expenses incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claims asserted,
but after deducting in the case of losses, claims, damages, liabilities and expenses suffered by the Company, any contribution
received by the Company from persons, other than the Underwriters, who may also be liable for contribution, including persons who
control the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, officers
of the Company who signed the Registration Statement and directors of the Company) as incurred to which the Company and one or
more of the Underwriters may be subject, in such proportions as is appropriate to reflect the relative benefits received by the
Company and by the Underwriters from the Offering or, if such allocation is not permitted by applicable law, in such proportions
as are appropriate to reflect not only the relative benefits referred to above but also the relative fault of the Company and the
Underwriters in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses,
as well as any other relevant equitable considerations. The relative benefits received by the Company and the Underwriters shall
be deemed to be in the same proportion as the total proceeds from the Offering (net of underwriting discounts and commissions but
before deducting expenses) received by the Company, on the one hand, and the underwriting discount and commissions received by
the Underwriters, on the other hand, in each case as set forth in the table on the cover page of the Prospectus, bear to the aggregate
initial public offering price of the Shares as set in the table on the cover page of the Prospectus. The relative fault of each
of the Company and of the Underwriters shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the
Company or the Underwriters and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contribution
pursuant to this Section 9 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such
purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in
this Section&nbsp;9. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party
and referred to above in this Section&nbsp;9 shall be deemed to include any legal or other expenses reasonably incurred by such
indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any judicial,
regulatory or other legal or governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such
untrue or alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this Section&nbsp;9, (i)
no Underwriter shall be required to contribute any amount in excess of the amount by which the discounts and commissions applicable
to the Shares underwritten by it and distributed to the public exceeds the amount of any damages which such Underwriter has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission and (ii)&nbsp;no person
guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;9, each of the Underwriter&rsquo;s
affiliates, directors, officers, employees and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act shall have the same rights to contribution as such Underwriter, and
each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of
the Exchange Act, each officer of the Company who shall have signed the Registration Statement and each director of the Company
shall have the same rights to contribution as the Company, subject in each case to clauses (i)&nbsp;and (ii) of the immediately
preceding sentence. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit
or proceeding against such party in respect of which a claim for contribution may be made against another party or parties, notify
each party or parties from whom contribution may be sought, but the omission to so notify such party or parties shall not relieve
the party or parties from whom contribution may be sought from any obligation it or they may have under this Section&nbsp;9 or
otherwise. The obligations of the Underwriters to contribute pursuant to this Section&nbsp;9 are several in proportion to the respective
number of Shares to be purchased by each of the Underwriters hereunder and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Underwriter Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If any Underwriter or Underwriters shall default in its or their obligation to purchase Firm Shares or Additional
Shares hereunder, and if the Firm Shares or Additional Shares with respect to which such default relates (the &ldquo;<B>Default
Shares</B>&rdquo;) do not (after giving effect to arrangements, if any, made by the Representative pursuant to subsection (b)&nbsp;below)
exceed in the aggregate 10% of the number of Firm Shares or Additional Shares, each non-defaulting Underwriter, acting severally
and not jointly, agrees to purchase from the Company that number of Default Shares that bears the same proportion of the total
number of Default Shares then being purchased as the number of Firm Shares set forth opposite the name of such Underwriter in <U>Schedule
I</U> hereto bears to the aggregate number of Firm Shares set forth opposite the names of the non-defaulting Underwriters, subject,
however, to such adjustments to eliminate fractional shares as the Representative in its sole discretion shall make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>In the event that the aggregate number of Default Shares exceeds 10% of the number of Firm Shares or Additional Shares,
as the case may be, the Representative may in its discretion arrange for itself or for another party or parties (including any
non-defaulting Underwriter or Underwriters who so agree) to purchase the Default Shares on the terms contained herein. In the event
that within five calendar days after such a default the Representative does not arrange for the purchase of the Default Shares
as provided in this Section&nbsp;10, this Agreement or, in the case of a default with respect to the Additional Shares, the obligations
of the Underwriters to purchase and of the Company to sell the Additional Shares shall thereupon terminate, without liability on
the part of the Company with respect thereto (except in each case as provided in Sections 6, 8, 9, 11 and 12(d)) or the Underwriters,
but nothing in this Agreement shall relieve a defaulting Underwriter or Underwriters of its or their liability, if any, to the
other Underwriters and the Company for damages occasioned by its or their default hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>In the event that any Default Shares are to be purchased by the non-defaulting Underwriters, or are to be purchased
by another party or parties as aforesaid, the Representative or the Company shall have the right to postpone the Closing Date or
Additional Closing Date, as the case may be for a period, not exceeding five business days, in order to effect whatever changes
may thereby be made necessary in the Registration Statement or the Prospectus or in any other documents and arrangements, and the
Company agrees to file promptly any amendment or supplement to the Registration Statement or the Prospectus which, in the opinion
of Underwriters&rsquo; Counsel, may thereby be made necessary or advisable. The term &ldquo;<B>Underwriter</B>&rdquo; as used in
this Agreement shall include any party substituted under this Section&nbsp;10 with like effect as if it had originally been a party
to this Agreement with respect to such Firm Shares and Additional Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Survival of Representations and Agreements</U>. All representations and warranties, covenants and agreements of
the Underwriters and the Company contained in this Agreement or in certificates of officers of the Company submitted pursuant hereto,
including the agreements contained in Section&nbsp;6, the indemnity agreements contained in Section&nbsp;8 and the contribution
agreements contained in Section&nbsp;9, shall remain operative and in full force and effect regardless of any investigation made
by or on behalf of any Underwriter or any controlling person thereof or by or on behalf of the Company, any of its officers and
directors or any controlling person thereof, and shall survive delivery of and payment for the Shares to and by the Underwriters.
The representations contained in Section&nbsp;1 and the agreements contained in Sections 6, 8, 9, 11, 12 and 18 hereof shall survive
any termination of this Agreement, including termination pursuant to Section&nbsp;10 or 12 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Effective Date of Agreement; Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>This Agreement shall become effective when the parties hereto have executed and delivered this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Representative shall have the right to terminate this Agreement at any time prior to the Closing Date or to terminate
the obligations of the Underwriters to purchase the Additional Shares at any time prior to any Additional Closing Date, as the
case may be, if, at or after the Applicable Time, (i)&nbsp;any domestic or international event or act or occurrence has materially
disrupted, or in the opinion of the Representative will in the immediate future materially disrupt, the market for the Company&rsquo;s
securities or securities in general; or (ii)&nbsp;trading on The New York Stock Exchange (&ldquo;<B>NYSE</B>&rdquo;) or Nasdaq
shall have been suspended or been made subject to material limitations, or minimum or maximum prices for trading shall have been
fixed, or maximum ranges for prices for securities shall have been required, on the NYSE or Nasdaq or by order of the Commission
or any other governmental authority having jurisdiction; or (iii)&nbsp;a banking moratorium has been declared by any state or federal
authority or any material disruption in commercial banking or securities settlement or clearance services shall have occurred;
or (iv)&nbsp;(A) there shall have occurred any outbreak or escalation of hostilities or acts of terrorism involving the United
States or there is a declaration of a national emergency or war by the United States or (B)&nbsp;there shall have been any other
calamity or crisis or any change in political, financial or economic conditions if the effect of any such event in (A)&nbsp;or
(B), in the judgment of the Representative, makes it impracticable or inadvisable to proceed with the offering, sale and delivery
of the Firm Shares or the Additional Shares, as the case may be, on the terms and in the manner contemplated by the Prospectus;
or (v)&nbsp;any of the events described in Sections 7(g) shall have occurred or the Underwriters shall decline to purchase the
Shares for any reason permitted under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Any notice of termination pursuant to this Section&nbsp;12 shall be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If this Agreement shall be terminated pursuant to any of the provisions hereof, or if the sale of the Shares provided
for herein is not consummated because any condition to the obligations of the Underwriters set forth herein is not satisfied or
because of any refusal, inability or failure on the part of the Company to perform any agreement herein or comply with any provision
hereof, the Company will, subject to demand by the Representative, reimburse the Underwriters for all reasonable out-of-pocket
expenses (including the reasonable and documented fees and expenses of their counsel), incurred by the Underwriters in connection
herewith; provided, however, that in the event of a termination pursuant to Section 10 hereof, only the non-defaulting Underwriters
shall be entitled to receive such reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Research Analyst Independence</U>. The Company acknowledges that the Underwriters&rsquo; research analysts and
research departments are required to be independent from their respective investment banking divisions and are subject to certain
regulations and internal policies, and that such Underwriters&rsquo; research analysts may hold views and make statements or investment
recommendations and/or publish research reports with respect to the Company and/or the Offering that differ from the views of personnel
in their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law,
any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the
fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent
with the views or advice communicated to the Company by personnel in such Underwriters&rsquo; investment banking divisions. The
Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to
applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short
positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the purchase and
sale of the Shares pursuant to this Agreement, including the determination of the public offering price of the Shares and any related
discounts and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several
Underwriters, on the other hand, (b)&nbsp;in connection with the Offering and the process leading thereto, each Underwriter is
and has been acting solely as a principal and is not the agent or fiduciary of the Company, the Subsidiaries or their respective
stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary
responsibility in favor of the Company with respect to the Offering or the process leading thereto (irrespective of whether such
Underwriter has advised or is currently advising the Company or the Subsidiaries on other matters) and no Underwriter has any obligation
to the Company with respect to the Offering except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters
and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of
the Company, (e)&nbsp;any duties and obligations that the Underwriters may have to the Company shall be limited to those duties
and obligations specifically stated herein and (f)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or
tax advice with respect to the Offering and the Company has consulted its own respective legal, accounting, regulatory and tax
advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Recognition of the U.S. Special Resolution Regimes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) In the event that any Underwriter that is a Covered Entity
becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and
any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective
under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of
the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) In the event that any Underwriter that is a Covered Entity
or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights
under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such
Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United
States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As used in this Section 15:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning
assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B>Covered Entity</B>&rdquo; means any of the
following: (i) a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;
252.82(b); (ii) a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b);
or (iii) a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B>Default Right</B>&rdquo; has the meaning assigned
to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B>U.S. Special Resolution Regime</B>&rdquo;
means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank
Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Notices</U>. All communications hereunder, except as may be otherwise specifically provided herein, shall be in
writing, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>if sent to any Underwriter, shall be mailed, delivered, or faxed and confirmed in writing, to such Underwriter c/o
Guggenheim Securities, LLC, 330 Madison Avenue, New York, New York 10017, Fax (212) 658-9689, Attention: Head of Equity Capital
Markets, with copies to the General Counsel and Underwriter&rsquo;s Counsel at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
One Financial Center, Boston, Massachusetts 02111, Attention: William Hicks, Esq.; <I>provided, however</I>, that any notice to
an Underwriter pursuant to Section&nbsp;8 shall be delivered or sent by mail or facsimile transmission to such Underwriter at its
address set forth in its acceptance facsimile to Guggenheim Securities, which address will be supplied to any other party hereto
by Guggenheim Securities upon request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>if sent to the Company, shall be mailed, delivered, or faxed and confirmed in writing to the Company at iCAD, Inc.,
98 Spit Brook Road, Suite 100, Nashua, NH 03062, Attention: Chief Financial Officer, with a copy to its counsel at Dentons US,
LLP, 1221 Avenue of the Americas, New York, NY 10020, Attention: Jeffrey Baumel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any such notices and
other communications shall take effect at the time of receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Parties</U>. This Agreement shall insure solely to the benefit of, and shall be binding upon, the Underwriters
and the Company and the controlling persons, affiliates, directors, officers, employees and agents referred to in Section&nbsp;8
and Section&nbsp;9 hereof, and their respective successors and assigns, and no other person shall have or be construed to have
any legal or equitable right, remedy or claim under or in respect of or by virtue of this Agreement or any provision herein contained.
This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the parties hereto
and said controlling persons and their respective successors, officers, directors, heirs and legal representatives, and it is not
for the benefit of any other person, firm or corporation. The term &ldquo;successors and assigns&rdquo; shall not include a purchaser,
in its capacity as such, of Shares from any of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">18.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Governing Law and Jurisdiction; Waiver of Jury Trial</U>. <B>This Agreement shall be governed by and construed
in accordance with the laws of the State of New York. </B>The Company irrevocably (a)&nbsp;submits to the jurisdiction of any court
of the State of New York located in the City and County of New York, Borough of Manhattan or any federal courts of the United States
of America located in the City and County of New York, Borough of Manhattan for the purpose of any suit, action, or other proceeding
arising out of this Agreement, or any of the agreements or transactions contemplated by this Agreement, the Registration Statement
and the Prospectus (each, a &ldquo;<B>Proceeding</B>&rdquo;), (b) agrees that all claims in respect of any Proceeding may be heard
and determined in any such court, (c)&nbsp;waives, to the fullest extent permitted by law, any immunity from jurisdiction of any
such court or from any legal process therein, (d)&nbsp;agrees not to commence any Proceeding other than in such courts, and (e)&nbsp;waives,
to the fullest extent permitted by law, any claim that such Proceeding is brought in an inconvenient forum. THE COMPANY (ON BEHALF
OF ITSELF AND, TO THE FULLEST EXTENT PERMITTED BY LAW, ON BEHALF OF ITS RESPECTIVE EQUITY HOLDERS AND CREDITORS) HEREBY WAIVES
ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT AND THE PROSPECTUS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">19.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The parties acknowledge and agree that, for purposes of Sections 1(c), 1(d), 1(e) and 8 hereof, the information provided
by or on behalf of any Underwriter consists solely of the material included under the captions: &ldquo;Underwriting&mdash;Commissions
and Discounts; Expenses&rdquo; (concerning the selling concession amount) in the Prospectus, the paragraphs under the caption &ldquo;Underwriting&mdash;Price
Stabilization and Short Positions&rdquo; in the Prospectus and the paragraph under the caption &ldquo;Underwriting&mdash;Passive
Market Making&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">20.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which shall be deemed
to be an original, but all such counterparts shall together constitute one and the same instrument. Delivery of a signed counterpart
of this Agreement by facsimile or other electronic transmission shall constitute valid and sufficient delivery thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">21.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Headings</U>. The headings herein are inserted for convenience of reference only and are not intended to be part
of, or to affect the meaning or interpretation of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="color: black">22.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Time is of the Essence</U>. Time shall be of the essence of this Agreement. As used herein, the term &ldquo;<B>business
day</B>&rdquo; shall mean any day when the Commission&rsquo;s office in Washington, D.C. is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the foregoing correctly sets forth your
understanding, please so indicate in the space provided below for that purpose, whereupon this Agreement shall constitute a binding
agreement among us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>ICAD, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By: <U>/s/ R. Scott Areglado</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;R. Scott Areglado</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted as of the date first above written</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>GUGGENHEIM SECURITIES, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: <U>/s/ Neil Oberoi</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Neil Oberoi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: Senior Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of itself and the other Underwriters
named in Schedule I hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Underwriting Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Total Number&nbsp;of&nbsp;Firm<BR> Shares to be Purchased</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">Number of Additional<BR> Shares to be Purchased if Option is Fully Exercised</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify; text-indent: -10pt; padding-left: 10pt">Guggenheim Securities, LLC</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">855,555</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">120,061</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">JMP Securities LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">116,111</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,294</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -10pt; padding-left: 10pt">Craig-Hallum Capital Group LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">91,667</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,864</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Lake Street Capital Markets, LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">85,556</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,006</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -10pt; padding-left: 10pt">Laidlaw &amp; Company (UK) Ltd.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48,889</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,861</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; padding-bottom: 1pt">Colliers Securities LLC</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,444</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,430</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: -10pt; padding-left: 30pt">Total</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">1,222,222</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">171,516</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Schedule
I</P>

</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Issuer Free Writing Prospectuses included
in the Pricing Disclosure Package</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule
II</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE III</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Company is selling 1,222,222 shares of Common Stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Company has granted an option to the Underwriters, severally and not jointly, to purchase up
to an additional 171,516 shares of Common Stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">The public offering price per share of Common Stock shall be $18.00.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule
III</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE IV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Stockholders executing Lock-Up Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Klein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stacey Stevens</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">R. Scott Areglado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jonathan Go</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nathaniel Dalton</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rakesh Patel, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andy Sassine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Susan Wood, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule
IV</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE V</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Written Testing-the-Waters Communications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Schedule
V</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Subsidiaries</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid">Name</P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt">Jurisdiction of Incorporation/Organization</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Xoft, Inc.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Xoft Solutions, LLC</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">PMDE ICAD</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">France</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Lock-Up Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guggenheim Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As Representative of the several</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Underwriters referred to below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Guggenheim Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">330 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>iCAD, Inc. - Lock-Up Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter agreement
(this &ldquo;Agreement&rdquo;) relates to the proposed public offering (the &ldquo;Offering&rdquo;) by iCAD, Inc., a Delaware corporation
(the &ldquo;Company&rdquo;), of its common stock, $0.01 par value (the &ldquo;Stock&rdquo;), pursuant to an Underwriting Agreement
(the &ldquo;Underwriting Agreement&rdquo;) to be entered into between the Company and Guggenheim Securities, LLC (&ldquo;Guggenheim&rdquo;),
as representative of the several underwriters named therein (the &ldquo;Underwriters&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to induce
you and the other Underwriters to underwrite the Offering, and in recognition of the benefit that such an offering will confer
upon the undersigned as a securityholder, officer and/or director of the Company, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, without the prior written consent
of Guggenheim, during the period from the date hereof until 90 days from the date of the final prospectus supplement for the Offering
(the &ldquo;Lock-Up Period&rdquo;), the undersigned (a) will not, directly or indirectly, offer, sell, agree to offer or sell,
solicit offers to purchase, grant any call option or purchase any put option with respect to, pledge, borrow or otherwise dispose
of, any Relevant Security (as defined below), and (b) will not establish or increase any &ldquo;put equivalent position&rdquo;
or liquidate or decrease any &ldquo;call equivalent position&rdquo; with respect to any Relevant Security (in each case within
the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder)
(the &ldquo;Exchange Act&rdquo;)), or otherwise enter into any swap, derivative or other transaction or arrangement that transfers
to another, in whole or in part, any economic consequence of ownership of a Relevant Security, whether or not such transaction
is to be settled by delivery of Relevant Securities, other securities, cash or other consideration. As used herein &ldquo;Relevant
Security&rdquo; means the Stock, any other equity security of the Company or any of its subsidiaries and any security convertible
into, or exercisable or exchangeable for, any Stock or other such equity security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; border-top-width: 0in; border-top-color: Black">The
restrictions in this Agreement shall not apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; border-top-width: 0in; border-top-color: Black">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">the transfer of Relevant Securities (i) as a bona fide gift or gifts, (ii) by will, other testamentary
document or intestate succession, (iii) to a Family Member (as defined below), (iv) to a trust for the direct or indirect benefit
of the undersigned and/or one or more Family Members, (v) by operation of law, including pursuant to a domestic order, divorce
settlement, divorce decree, separation agreement or pursuant to an order of a court of competent jurisdiction enforcing such agreement,
(vi) to a charitable trust, or (vii) to a corporation, limited liability company or partnership wholly owned by the undersigned
and/or one or more Family Members;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">the transfer of Relevant Securities (i) as forfeitures to satisfy tax withholding obligations of
the undersigned in connection with the vesting or exercise of equity awards by the undersigned existing as of the date of the final
prospectus supplement and described or incorporated by reference in the final prospectus supplement, (ii) pursuant to a net exercise
or cashless exercise (to satisfy exercise price or related withholding obligations) by the undersigned of outstanding equity awards
existing as of the date of the final prospectus supplement and described or incorporated by reference in the final prospectus supplement,
provided that any shares of Stock acquired upon the net exercise or cashless exercise of equity awards described in this clause
(b) shall be subject to the restrictions set forth in this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify">distributions of Relevant Securities to limited partners, limited liability company members or
stockholders of the undersigned;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify">transactions relating to Relevant Securities acquired in the Offering or in open market transactions
after the closing of the Offering;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify">to the undersigned&rsquo;s affiliates or to any investment fund or other entity controlled or managed
by or on behalf of the undersigned or one or more of its affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">f)</TD><TD STYLE="text-align: justify">to the Company upon a vesting event of the Company&rsquo;s securities, pursuant to arrangements
under which the Company has the option to repurchase such shares or a right of first refusal with respect to transfer of such shares
or upon the exercise or conversion of options or warrants to purchase the Company&rsquo;s securities, in each case, on a &ldquo;cashless&rdquo;
or &ldquo;net exercise&rdquo; basis or to cover tax withholding obligations of the undersigned in connection with such vesting
or exercise, provided that (i) any filing under Section 16 of the Exchange Act made during the Lock-Up Period shall clearly indicate
in the footnotes thereto that (A) the filing relates to the circumstances described above and (B) no Relevant Securities were sold
by the reporting person other than such transfers to the Company as described above and (ii) the undersigned does not otherwise
voluntarily effect any other public filing or report regarding such transfers during the Lock-Up Period; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">g)</TD><TD STYLE="text-align: justify">the transfer of Relevant Securities pursuant to a bona fide third-party tender offer for all outstanding
shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company&rsquo;s securities
involving a change of control of the Company (including, without limitation, the entering into of any lock-up, voting or similar
agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Relevant Securities in
connection with such transaction, or vote any Relevant Securities in favor of any transaction), provided that in the event that
such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall
remain subject to the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It shall be a further
condition to any transfer or distribution pursuant to the preceding clauses (a), (b), (c), (d), or (e) that no public disclosure
or filing by any party (donor, donee, transferor or transferee) under the Exchange Act, or other public announcement shall be
required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on Form 5 made after
the expiration of the&nbsp;Lock-Up&nbsp;Period).</P>

<DIV STYLE="padding: 12pt 0in 0in; border-top-width: 0in; border-top-color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It shall be a condition
to any transfer or distribution pursuant to each of the preceding clauses (a), (c), or (e) that (x) any such transfer shall not
involve a disposition for value and (y)&nbsp;each resulting transferee or donee of Relevant Securities executes and delivers to
you an agreement satisfactory to you in which such transferee agrees to be bound by the terms of this Agreement for the remainder
of the&nbsp;Lock-Up&nbsp;Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this
Agreement, the term &ldquo;Family Member&rdquo; shall mean any relationship by blood, domestic partnership, marriage or adoption
not more remote than first cousin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;In addition,
the restrictions described in this Agreement shall not apply to the establishment of a trading plan pursuant to Rule 10b5-1 under
the Exchange Act, provided that no transfers occur under such plan during the Lock-Up Period and no public announcement or filing
shall be required or voluntarily made by any person in connection therewith other than general disclosure in Company periodic reports
to the effect that the Company directors and officers may enter into such trading plans from time to time.&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby
authorizes the Company during the Lock-Up Period to cause any transfer agent for the Relevant Securities to decline to transfer,
and to note stop transfer restrictions on the stock register and other records relating to, Relevant Securities for which the undersigned
is the record holder and, in the case of Relevant Securities for which the undersigned is the beneficial but not the record holder,
agrees during the Lock-Up Period to cause the record holder to cause the relevant transfer agent to decline to transfer, and to
note stop transfer restrictions on the stock register and other records relating to, such Relevant Securities. The undersigned
hereby further agrees that, without the prior written consent of Guggenheim, during the Lock-Up Period the undersigned (x) will
not file or participate in the filing with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) of any registration
statement, or circulate or participate in the circulation of any preliminary or final prospectus supplement or other disclosure
document with respect to any proposed offering or sale of a Relevant Security and (y) will not exercise any rights the undersigned
may have to require registration with the SEC of any proposed offering or sale of a Relevant Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; border-bottom-width: 0in; border-bottom-color: Black">It
is understood that, if (i) the Company notifies the Underwriters that it does not intend to proceed with the Offering, (ii) the
Underwriting Agreement does not become effective on or before April 30, 2021, (iii) the Underwriting Agreement (other than the
provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Stock,
or (iv) the closing of the Offering pursuant to the Underwriting Agreement has not occurred by April 30, 2021, the undersigned
will be released from its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; border-bottom-width: 0in; border-bottom-color: Black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; border-bottom-width: 0in; border-bottom-color: Black"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; border-bottom-width: 0in; border-bottom-color: Black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that the Company and the Underwriters will proceed with the Offering in reliance on this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not the
Offering actually occurs depends on a number of factors, including market conditions. Any Offering will only be made pursuant to
the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby
represents and warrants that the undersigned has full power and authority to enter into this Agreement and that this Agreement
constitutes the legal, valid and binding obligation of the undersigned, enforceable in accordance with its terms. Upon request,
the undersigned will execute any additional documents necessary in connection with enforcement hereof. Any obligations of the undersigned
shall be binding upon the successors and assigns of the undersigned from the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Agreement shall be governed by and
construed in accordance with the laws of the State of New York. Delivery of a signed copy of this Agreement by facsimile transmission
shall be effective as delivery of the original hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">By: _____________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Print Name: _______________________</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>SIGNATURE PAGE TO ICAD LOCK-UP AGREEMENT</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>e620354_5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 35px; width: 113px"></FONT></TD>
    <TD STYLE="width: 30%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dentons US LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1221 Avenue of the Americas</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10020-1089 USA</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T +1 212 768 6700</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">F +1 212 768 6800</P></TD>
    <TD STYLE="width: 25%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #6E2D91">Salans FMC SNR Denton</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">dentons.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 2, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">iCAD, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">98 Spit Brook Road, Suite 100&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nashua, New Hampshire 03062</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re:</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">iCAD, Inc.--Registration Statement on Form S-3</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">In our capacity as counsel to iCAD, Inc.,
a corporation organized under the laws of the State of Delaware (the &ldquo;<U>Company</U>&rdquo;), we have been asked to render
this opinion in connection with a registration statement on Form S-3 (File No. 333-235887) (the &ldquo;<U>Earlier Registration
Statement</U>&rdquo;) and the Registration Statement filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended (the
&ldquo;<U>Securities Act</U>&rdquo;) relating to such Earlier Registration Statement (the &ldquo;<U>462(b) Registration Statement</U>&rdquo;
and together with the Earlier Registration Statement the &ldquo;<U>Registration Statement</U>&rdquo;), which Registration Statement
the Company was filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) under the Securities Act,
and the prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act and dated March 2, 2021 (the &ldquo;<U>Prospectus
Supplement</U>&rdquo;), under which 1,222,222 shares (the &ldquo;<U>Firm Shares</U>&rdquo;) of Company common stock, par value
$0.01 per share (&ldquo;<U>Common Stock</U>&rdquo;), are being sold by the Company pursuant to the Underwriting Agreement, dated
March 2, 2021 between the Company and the representative of the underwriters named therein. The Company has also granted an option
to the underwriters to purchase up to an additional 171,516 shares of Common Stock (the &ldquo;<U>Option Shares</U>,&rdquo; together
with the Firm Shares, the &ldquo;<U>Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">We are delivering this opinion to you
at your request in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5) of Regulation S-K under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">In connection with rendering this opinion,
we have examined originals, certified copies or copies otherwise identified as being true copies of the following: (i) the Company&rsquo;s
certificate of incorporation, as amended, (ii) the Company&rsquo;s amended and restated by-laws, as amended, (iii) the Registration
Statement, including the prospectus contained therein (the &ldquo;<U>Base Prospectus</U>&rdquo;), (iv) the Prospectus Supplement
(the Base Prospectus and the Prospectus Supplement are collectively referred to herein as the &ldquo;<U>Prospectus</U>&rdquo;),
(v) corporate proceedings of the Company relating to the Shares and (vi) such other instruments and documents as we have deemed
relevant under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">In making the aforesaid examinations,
we have assumed the genuineness and authenticity of all documents examined by us and all signatures thereon, and the conformity
to originals of all copies of all documents examined by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">Based on the foregoing, and in reliance
thereon, and subject to the qualifications, limitations and exceptions stated herein, we are of the opinion that the Shares have
been duly authorized and, when issued and delivered by the Company against due payment therefor in accordance with the terms set
forth in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">The foregoing opinion is limited to the
laws of the State of Delaware (excluding local laws) and the federal law of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">We hereby consent to the use of our opinion
as Exhibit 5.1 to the Registration Statement and to the reference to this firm and this opinion under the heading &ldquo;Legal
Matters&rdquo; in the Prospectus comprising a part of the Registration Statement and any amendment thereto. In giving such consent,
we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities
Act, or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Dentons US LLP</P></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>e620354_99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>iCAD Announces Proposed Public Offering
of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NASHUA, NH, March 2, 2021 -- iCAD, Inc. (the &ldquo;Company&rdquo;,
NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced
that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in
the offering will be offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company intends to grant
the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guggenheim Securities is acting as sole book-running manager
for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to use the net proceeds of the offering
for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities described above are being offered by the Company
pursuant to an effective shelf registration statement on Form S-3 (File No. 333-235887) previously filed with the Securities and
Exchange Commission (&ldquo;SEC&rdquo;) on January 10, 2020, which registration statement was declared effective on January 31,
2020. The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that
form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and
describing the terms of the offering will be filed with the SEC and will be available on the SEC&rsquo;s website at http://www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when
available, from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by
telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or
the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">About iCAD, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Headquartered in Nashua, NH, iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements contained herein constitute &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995. For example, when the Company discusses
the timing and success of the proposed offering and the anticipated use of proceeds from the proposed offering, it is using forward-looking
statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company&rsquo;s
ability to achieve business and strategic objectives, increase sales and acceptance of products, adoption by CMS of a new payment
model, and that such model will prove beneficial to the Company, which is not assured, implement expansion plans, the risks of
uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales
levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties,
product market acceptance, possible technological obsolescence of products, increased competition, to successfully defend itself
in litigation matters, government regulation, changes in Medicare or other reimbursement policies, risks relating to the Company&rsquo;s
existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company,
the effects of a global pandemic, and other risks detailed in the Company&rsquo;s filings with the SEC. The words &ldquo;believe,&rdquo;
&ldquo;demonstrate,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;will,&rdquo; &ldquo;continue,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;likely,&rdquo; &ldquo;seek,&rdquo; and similar expressions identify forward-looking statements.
Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement
was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional
disclosure regarding these and other risks faced by the Company, please see the disclosure contained in the Company&rsquo;s public
filings with the SEC, available on the Investors section of the Company&rsquo;s website at http://www.icadmed.com and on the SEC&rsquo;s
website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media Inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jessica Burns, iCAD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1-201-423-4492</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jburns@icadmed.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeremy Feffer, LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+ 1-212-915-2568</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jeremy@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>e620354_99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>iCAD Announces Pricing of $22.0 Million Public Offering of
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NASHUA, NH, March 3, 2021 -- iCAD, Inc. (the &ldquo;Company&rdquo;,
NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced
the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of $18.00 per
share. The gross proceeds of the offering to the Company are expected to be approximately $22.0 million, before deducting the underwriting
discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day
option to purchase up to an additional 171,516 shares of common stock at the public offering price, less underwriting discounts
and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The closing of the offering is expected to occur on or about
March 5, 2021, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guggenheim Securities is acting as sole book-running manager
for the offering. JMP Securities, Craig-Hallum Capital Group, and Lake Street Capital Markets, LLC are acting as lead managers
for the offering and Laidlaw &amp; Company (UK) Ltd. and Colliers Securities LLC are acting as co-managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to use the net proceeds of the offering
for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities described above are being offered by the Company
pursuant to an effective shelf registration statement on Form S-3 (File No. 333-235887) previously filed with the Securities and
Exchange Commission (&ldquo;SEC&rdquo;) on January 10, 2020, which registration statement was declared effective on January 31,
2020, and an additional registration statement on Form S-3MEF (File No. 333-253808) filed pursuant to Rule 462(b) under the Securities
Act of 1933, as amended, on March 2, 2021, which registration statement became automatically effective upon filing. A preliminary
prospectus supplement relating to the offering was filed with the SEC on March 2, 2021 and is available on the SEC&rsquo;s website
at http://www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with
the SEC and also will be available on the SEC&rsquo;s website. Before investing in the offering, you should read each of the prospectus
supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that the Company
has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating
to the offering, which provide more information about the Company and the offering. Copies of the final prospectus supplement and
accompanying prospectus relating to the offering may be obtained, when available, from Guggenheim Securities, LLC, Attention: Equity
Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or
the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">About iCAD, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Headquartered in Nashua, NH, iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements contained herein constitute &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995. For example, when the Company discusses
satisfaction of customary closing conditions to the offering, the expected gross proceeds from the offering and the anticipated
use of proceeds from the offering, it is using forward-looking statements. Such forward-looking statements involve a number of
known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the
Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking
statements. Such factors include, but are not limited, to the Company&rsquo;s ability to achieve business and strategic objectives,
increase sales and acceptance of products, adoption by CMS of a new payment model, and that such model will prove beneficial to
the Company, which is not assured, implement expansion plans, the risks of uncertainty of patent protection, the impact of supply
and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary
rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence
of products, increased competition, to successfully defend itself in litigation matters, government regulation, changes in Medicare
or other reimbursement policies, risks relating to the Company&rsquo;s existing and future debt obligations, competitive factors,
the effects of a decline in the economy or markets served by the Company, the effects of a global pandemic, and other risks detailed
in the Company&rsquo;s filings with the SEC. The words &ldquo;believe,&rdquo; &ldquo;demonstrate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;will,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;likely,&rdquo;
&ldquo;seek,&rdquo; and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation
to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks
faced by the Company, please see the disclosure contained in the Company&rsquo;s public filings with the SEC, available on the
Investors section of the Company&rsquo;s website at http://www.icadmed.com and on the SEC&rsquo;s website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media Inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jessica Burns, iCAD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1-201-423-4492</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jburns@icadmed.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeremy Feffer, LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+ 1-212-915-2568&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jeremy@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>icad-20210302.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /KM5s7xRiXgOn8uFZXIsSamLScP9wZJ1yelBsG18fdl6jywsghbp3yIaCWMGQQUB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:ICAD="http://icadmed.com/20210302" elementFormDefault="qualified" targetNamespace="http://icadmed.com/20210302">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://icadmed.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="icad-20210302_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="icad-20210302_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>icad-20210302_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>icad-20210302_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://icadmed.com/role/Cover" xlink:href="icad-20210302.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://icadmed.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  C '$# 2(  A$! Q$!_\0
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MOHXG%4]91C?6;NY)=(OOV1]U0RK+UA:=6M'5I?S;OR1]G_\ $4/'_P!$0?\
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M?Q'F_:F\-)X(U#4FT>WU4^$;ORI;M0Q:(+YN_("MSMQQUKS/]G?_ ()^Z/\
M$;X+ZO\ %+X@?$[2?AK\,K+6'T+3M5ETV6_NM=N5SQ!;HP;;@=<D\-Q\I-8Q
MR?AR4'-4W9.W_+W?LENWY+5&:P&4N+DH/1V^WOV\WZ'VC_Q%#Q_]$0?_ ,+
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-_]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>e620354_8k-icad_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="icad-20210302.xsd" xlink:type="simple"/>
    <context id="From2021-03-02to2021-03-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749660</identifier>
        </entity>
        <period>
            <startDate>2021-03-02</startDate>
            <endDate>2021-03-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-03-02to2021-03-02">0000749660</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-03-02to2021-03-02">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-03-02to2021-03-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-03-02to2021-03-02">2021-03-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-03-02to2021-03-02">iCAD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-03-02to2021-03-02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-03-02to2021-03-02">001-09341</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-03-02to2021-03-02">02-0377419</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-03-02to2021-03-02">98 Spit Brook Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-03-02to2021-03-02">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-03-02to2021-03-02">Nashua</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-03-02to2021-03-02">NH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-03-02to2021-03-02">03062</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-03-02to2021-03-02">(603)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-03-02to2021-03-02">882-5200</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName contextRef="From2021-03-02to2021-03-02">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications contextRef="From2021-03-02to2021-03-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-03-02to2021-03-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-03-02to2021-03-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-03-02to2021-03-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-03-02to2021-03-02">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-03-02to2021-03-02">ICAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-03-02to2021-03-02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-03-02to2021-03-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140525807273416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  02,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-09341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iCAD, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000749660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">02-0377419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">98 Spit Brook Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashua<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">03062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">882-5200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ICAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not Applicable<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MHU^D"JI'&=><?<'0RKG!QRW]/=I<IQ9,Y@^9G'\Q<$7:IEV&L963@X\[>SZ
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M_@-#WIZYY3:\ 8]B WX+,^2^%1=&A.=SB=]EIBT9)PE8$U]%E>#>R1+:?8Z
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 1(-D4F7@#P3N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 1(-D
M4IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !$@V12RQZSJVH$  !S$0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 1(-D
M4H.II0/4 0  ,@8   T              ( !K0P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !$@V12EXJ[',     3 @  "P              @ &L#@
M7W)E;',O+G)E;'-02P$"% ,4    " !$@V12JL0B%C,!   B @  #P
M        @ &5#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 1(-D4B0>
MFZ*M    ^ $  !H              ( !]1   'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 1(-D4F60>9(9 0  SP,  !,
M     ( !VA$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&)!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="e620354_8k-icad.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://icadmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="e620354_8k-icad.htm">e620354_8k-icad.htm</File>
    <File>e620354_1-1.htm</File>
    <File>e620354_5-1.htm</File>
    <File>e620354_99-1.htm</File>
    <File>e620354_99-2.htm</File>
    <File>icad-20210302.xsd</File>
    <File>icad-20210302_lab.xml</File>
    <File>icad-20210302_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e620354_8k-icad.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "e620354_8k-icad.htm"
     ]
    },
    "labelLink": {
     "local": [
      "icad-20210302_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "icad-20210302_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "icad-20210302.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 60,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ICAD",
   "nsuri": "http://icadmed.com/20210302",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e620354_8k-icad.htm",
      "contextRef": "From2021-03-02to2021-03-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://icadmed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e620354_8k-icad.htm",
      "contextRef": "From2021-03-02to2021-03-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://icadmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193805-21-000331-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193805-21-000331-xbrl.zip
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M&#TAU@=@5F4:WC.J(%)WA+ Y#>D&X^"K,$_Z#@D+S/8#):_FOV;IQ#%W$W3
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M)$"8W;F>AS=,]=LC/O7@.L>G'MS&IZXS>0]8-JNK8MDT[9B7>R5'>#V!==+
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M@]#38Q?.C,BRN"[: =:I)9N.BKXRG6  5@BEH_83-X.-%8-0-]C*E"K?6(D
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M<0IYP3I-Z!ZKX'OJ&QY2Y;]ZI"F (-1/*'+%/"D%D)>R;DHN#@A@]:BTOFR
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M.85:G]7B&&V9)[1,)K60,:DW=D_(P<<J ^^)&\UAK,(_,I^W[IJC=>ZL#N*
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MTI@/ :7S>&3/[<#5<9<,Z1]HHE@8ML "2/22;ZC8D8)&;H!#6RVS/R%3TL(
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MEGYM"L:O )_CT?&/W]^GA&X!^+21_&>O7[PY#2/X**U[E6]NNJ076,9YXC!
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MD]^>RUP>GG_2"=$][3^ACJX&S*,>GB#/ZN-2L<=I:5KF+2)SW3.KNE@+CJ5
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MN:OT;JH(05LF')D!2$$\*<XO%GRH0]!K' KW:UJN*B._?_1@0 L0/'!U*KU
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M^SC)XP<',Y=YTAE3[<X[Z09/M+/^*FUXOZ5;F%^56SAT(U^$2C=52$N/[:4
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M-JM5(J!?#=4-L].IKRY]?^ #E[XE9<O?0/'*O# *&86TRS1;3<"^%S#/=)Z
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M$VHKJJRF'Z,$QJ9N*5=K%40\KN187.7.T81N!G+U<0-6K7BP92TN4$;9-LX
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M:,"M@@=/CIQGP:*((T@9>@[K )4.H_.X+%@> J)+8_IEDJUPK<DJ.6OB %V
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M,A\485W>XZP]OY7JG-/+/DN L7#,MK,L3#1E?R@*3CX]C6E+7?&#J1H%/C&
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M2Q@L""OX1U'Q,.K:J";-:2_U=$N+2R :E.R$[&1<R]4CZ$P*86)UBQT#"&P
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M'T$98 $ Z%_NKB5^''9QN?_>(M'A=NW+."^5RJN"03DM%ZI 0@/R$+Z/"Y2
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M89Y/0#Q0)@I?W]3P(/CC^";SGCK)UE-YYP^:O@)@'?2Y8.M@9PU-@T>W N_
M*@23[$7QPCM>\TX&H%_A4HC.DR#,T"+[<0LR?9YT0=EV9<-L%V.FU&CA3+6E
ME*]IPB]('[U=Q&['9V^[5($;$;*96.8A45C$.3;)GV5(<I%CRB)=W*9-.O0?
M/GWXT#OXV.OO>R>]G4_'_=-^[X3*S5D)+.[DK?-Z$,4@2V=1GL5\4F_M(6P-
M.N/?VMA\/."7*5*^[ =I<$X,+U*CM+AKWV)/'-K1>N&Q5V&Y.A'W\E(:2 WQ
MR> B"B?8DR4%7S_:]+F/3]$>6O_MOXP32@9\::%6H41I"_3?Z)<^&K>TL]C.
MZ)/WN*C2=;+SL;?["9RA_H\]*\8#LSVNJD>FA*/-QWKC6<[9#(>+Q:#!YYK_
M-1L#<HW'IP.#R?%QZ)S1Z#-/GO[5!F=S'(3H0NMO="H^A7FWG4-<R(._/WOY
MK,5FG3WSTPS9K XHW\4/R8;\-Q+]_/;N^*W%FGH&"EEQI?_<][SAT\#PT1D]
MPU8TY>T0_>10>+4*[_T$NV)["D-E3D>$)P=; ',[S[-)&CZ7@'Y^?K:RL?[*
MWWBYY6]L;JY.#1(T+-WLH/%S=XV3:%BJE6AOR*QNJ<QAHRG^,$?@HC-KZC@K
MUUVNC[$Y:Q!J('CV=FMST]_<W&P;YA:F<B^6H;.Q[J^_[MS>,GR'E'^^ 'W8
MHHMGB?.SM[_O']D=F@WB>:/-^.8=F&O5.Z_]3J>VZK?US)_Y9J_]C>U7W_EB
M=ZLI;U<[[N1!?/[\8Y DDY'J(?<^P)S&BRV"VQW_]>M?'J($;OA;KW^B!'Z?
M%MO#UE'!7U'2I $)%EJ@MO ^??TP!6I]_7M?[#ZIM+T@#I/@ROM;,!J_T<T?
M*Y_^L>KME>':XN[4JRU_:VO[ 8K@:U!IWVLMW(%*N[$+URB6C7[=#O:X(AKY
M=)/N#IW(VWC':?O^70.+7&R\\E^]JMUUBS/EA[7:+_U7+]?O>+%_\#U!/[B*
M\/UPZ"3\YJOC)6<\,3HT4U'5GGI#U3ICUC?2MC/&4C: O[&Q@?__WO&^;VZ+
MOTZ_=/S-SFQCZ<8SJR;%[S@DO3A)G!]347B[Z0-)9RXOF?S!4X9G03,\/SC%
M<S</Z1?%),J]]]B1]UF2OJ;[*BIT+YPB>_2P@8R+#8I!DA6<.AY\@>V]7^OQ
M[.U!EMXB-NY/HHUX^7*Q<]662NL_9:Q_3IU-@^Y:R/STY_[NZ<>_/Z/L\[?.
M:NKV@[3,K&:LYW+H)#9F>01>KU.+[#1&*!U D$*W_&H+&:N\<VZ#QLX9@IS(
M!E_6C!W7;,7-)??SKN,CV[J-FV\=(KR?YP&QMF,#*N>N!7["99D4\DGIW,.N
MO?]D,;(+$A:')NJ<C*FAE5@35<;<$X?@22A^O%"\G%\HFLE0Q\@VB?M6W3;3
ME?>7SM;:^OI/WL9OUOVS=F4>P^75_3%<GBR7FTK #[9G_KA?OD=+5./3VQ.+
MHE>@$@CJ#'[Z_-/8E.,6MUJL_H/\K?T8KKLH\?Z11/%M-C><E,$@N@8%BV1F
MQ2T.W- ><VMC_PZ7/*%;?;C-40]H3#CHWFZ0E-EMKO)Q\"4J+D"-EU'B>_MK
MN[?I.G?3$#80H6'2VPLC@&1,"ECASUD6^M[1Q>U.^>=X^YOWYM+\X^G.7!!O
M_Z%<CI^Y+<X[C0J\%9^#O_7\<T#,VSL.F/Q]O!P?1C#R]7U13T_:Z2=KI]X_
M/_;?]4^][OTZJ.V6^^2LB,,XR(7KX&?%5V^*P%"OAKC"FJ4I2 P-,OIMG4+T
MH.<$C?&KEV97>3#6'4BO-O^JOD'?^OY5K*B7LVI[#O;K\BF;AA Q TAB^D/<
MMYO> ?][!7&WGUK, "\.\W,P\QF]L;EGOSZWQOC8]$G\,QN63,1C/V3FR&K'
MIZW4-\QF-TJ"JR"/9KWPC-:FC9:ZH5M;,>]$J"I5X?'3TLTSQZ/]W9Z'2"*+
ML&#OB2CT;M$E;E!&,\WF^F6Q;:ZG9N5%M5J4"?;N@9A@[Y%S%Z[*6K3T/OJ#
MTWI';_=-*EQQW<([=@B-%$R-)#/O^/%V M4AVB+,M#M^^*WOXN!%*[?F;>[D
ML[=U?M?;C$VT$,4N;KBB54<8:DGO^<-0%'NPZT)/]P&>D>"+W!Y7],_D2R4
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M5@W%<C1)SHDPC70VR=6J*X?V0Y04KOKN[M$-Q/</<99=!6/D#,]A@?C*4.K
M(FPC8K<\QZ'I-)"RHM\/"1*0QJ)O^40N?I$Q 0?\-U(CL)2 [DNS$5@!=)(%
MCAO);J]2&.0B'C/51VWQ"9F99@0CHMR0EK1FM[P4*V"C @R6A/G&0HM I#HF
M7:?\EH7U$]C<"_/^CO*KXO2K%5<C+R^IZ2K!0L$HA#F0K ]#.TNTP-=::U?4
MLL6BAR9,8>4VF(,BM;Y*E!5Y&9]A7@TWE78[8@@GTN'T3Q8+^C=H,IX+UT3J
MUZ55K<SLD5WZ<T7\MIXB?@\FXK=H<KCQRI(26-WGJC0Z3IT?2[+P'1.FG%[
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MQXH=>]"$Q@OA)91<F/TDA"Z@U*'&+,@CG8\A9T]923E,B)#)<"+,3046V*0
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M-8S-49)!-BGB])'M$S^Y;_ K=:&VE>BJY\JFU0:Q.:W*<T<2$L.BC8 K)Y+
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MPK#V]@YW_O'\TY'7_7#<Z^WW#DY_@CWTXMWA[I\D.!]/]_?>_C]02P,$%
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MNBT>GZ0O1Q$ ]U&U%@0I-L]1I:"DB+B% .OB[!T-GWH-8QX@6!GF(L'OS9L
M5OE#2[2 O+&(W(]B7U3:=P\*T_"Y<N$1$ BA))FAOL/79RVY;9P0=5V*VB=^
M-0/!K3T=Z7T(6H6LQ%4R0P-'' *D]?#Y8@F 0E;9[:T6T$33N.E"L74%F0@L
M!^+(@E6GP=8,\'A$1 *? ZZ"7:3"^@T\0*N[H0; VCQ\T::0A5,CM&(_+/GA
M/; G2 H4V-IB?BCZ(\LL^<M<9X%OV8PBO08%7"R21D$1ZW0;WN[2EOL+T1 9
M( 9,]> %[>\>6D\+\:_>]_PCLZ'!^RT'(CH.\_(I0.LB>YR<7T7!R]E9TR].
M9;]UF<&JJA2+-AO%<UW_!+$(DM*4,;WJ JE$"^YYJ>V7WD$*3?NY !0EW E_
M:IX3Q'C40M@1?DQ"++ =RQLF+1-2@<P B.&':!HB5@?+<9C*P'*T>.XA?Y3!
MA8+, ^X8RV=":'1;[B?N>(=A"= _*CMV#Q#16$)Q$:B8A2IE?J 1WT<SBR-)
M0(6&6"7"- %?/<=9+N#BK1K1XD&+^$<X?D4T&:_9T#/DHH];J$;,AI[#_D%.
M+MPCUM:(>Q5F!+PQ(IXT<YC! 'N"65'3A&RC!@YA4/@P"B%/ #>">@:AJCBP
M'[^>!H*B:P!V;@!4:4)R8O-")<:2(+ =>(ZI\Q&Z]SRI<%*K^6D%?E'B1-/2
MU"'?--$&S>#)BK#_4,V<2K_3YP^7"!B&R$@+"RP@$.X[EG1^08;W19.%"'LM
MH<P"7D>XR,/ ?O&#Y9 (5",*D0KO?P'JU- 1M:"F%_T$OY2/E4Z(!N=WJZI$
M?@HB3=*-VY5]@^C@><,.>(ER<H*P=@$:1JI1(8<[@C*%2V'2*Y<$D_ML=>XG
M?HMZMJ)QBK;QH%L>1]$&GNLYP3,A06<W\5[X\E'*MQUKUKCUIOQ[Z^UWNO6V
MN015$PGJ.+SQW0WZDD'O4X:M[&:?,'N9!>%K!@.!7U;<-W#K<^4A8)]ZY<_%
M%VP_=4C4%QW6K)LIL<Z7/Z<9%'P75@0+2:=Z]$!LZ8D#L?ZP:G7%@=>G=/$K
M9ABLJ<6XZNBBK;/VV=.E4 ,%_YJ/#SRFCN6;X)3(UX"SLI(OEO;N"IE"=N2"
M/:VZL9=PAR>-R1BC1)^Y$\;,Z!UF_'KU'=_#'-W,.=Q4O;1*06N^&^?7#UPF
M:+,4://2;Z, /HFW83:H :4(B/(-ZZ )JQ:W\A9U0'9B-P0BS9_=#:H'<+;Q
M]K13JP7JN8K6+TENMEE=**][&CEYZ<I32R^N6/J;/G*S#A O_@O$_P7B"X"A
MVWE_T>C=7&_Z3?@O(.W50F?0P3] Y/@%P_+1\F@-+<I^V57 4=?Q([V:9\R(
M2CTNS@OI/'B?M>P <# #>4@"6RA]-J+&(&@3BCK>'R":@QXV!00]ZKDCRP%[
MT5ZP@'\#M4#\&.03;Q<L;O01L/@+GS?Z<%<J^O:=W>>_4'%C;UD,:H[*S[R%
M-7CT+NDHZM%L_^>>YWOB=;&%7WQ<\-&%U))6DN,Y<JZ#LS.#G!I,-Y_Y[LO'
M#/LY$WX&ML0KZ0V9[H(R-NP8S9'.!DOO<'.6?.1-PR5\B?^^C_?V KSW4E$Z
MAW^B3*@$_QY>?<T_B%8]NA,/E<BS%?,_I,9.IL??M/SIY%OC?'1;&U:F1^6S
MONV=.IW*AY[3/NV=M!^:A;YQ>?;YVUGOKZO;DP>JY3]^G#7N2\5)Z>-PVK[6
M7:U3O;!OV/5D<DI=X^;<JG9FY_9][Z%[P?I'5Q->/3UUORJ?5#=7:1BM6<NT
M[\_M\N><5BU77&-HM,_I-[4U.SUIZ[?3UN77?O[+I/#I?'9;4$;J)^>3U9X<
MLS+]?-%SCIU<I?6Q5SRYN;KZ?F]5.I_LBY./C4KKBUEJ'9];'<V\_M+ZZ]09
M]:97U[V6=3IJW.;+Q=K4G7%K@C2^_C4#-3[LG5\5;..DU7CW3JKD_P%02P,$
M%     @ 1(-D4L_&F+PX"@  C"$  !    !E-C(P,S4T7SDY+3$N:'1MS5IM
M;]LX$OYNP/^!VP]%BY.3V&EVVS07U$W2;8JTFZUS!_0C)=$V&XE4^&+'^^OO
M&5*2'=O-]7!>($41.Q(YG'EF.//,("<?;SY?G78[)Q\OAN?X9/3OY.;RYNKB
M]&0_?N+M?OWZY/T?Y]_8Z.;;U<4_GXVU<L>L?U Y=B-+8=D7,6=?=<E5$A\D
M;"2,'#_#1FR];O:5W$RD.F;8^.STN4IM]?9D_WIMT<\*?\M6Q+&#M\R)>]?C
MA9S@42:4$^;9Z<G[4WDV/&=#I;17&:1=&UUI*W)V[=-"9NR/\1C2U*3;T6-V
MILM2*S9R.KL]V7]_^C=KMV,(GIU^&8X^_FN8L"\?$_:9FVS*!@D;' SZK-=C
M!$3"+E6VQUZXJ6#/B_S.Z[>PN>)J\=R$WY)N!T+.AW\>LTNL?YDPSB:%3GG!
M2I'+#)].9%.E"SU9L$+P7!A6&3V3.4!D$CC/N),SP3(.O W+!=8["52YRAG.
M-;Q:,*L+3P]AB=,Y7^!E=%#>[;@I=TSB/T!2N<4"ILE)08 51<'LE!N@ H=)
M9UD6G6;):=B$9<PKJ#4WTD$"JZ*C=>WH/3:$".PE#&I)."(5I%0. :2!:)>S
MN<3RM'Z N$D786<-VQZ[65TL+;,^_0Z+22:\<RL<%%2Y#-:V& 1X2*K2C%OK
M#8&%;[1K/A6T! %IZ+MB#]0I 1;VP>BJ +1YPK L;J1U/',>/K+R+T$O$&:E
M;8Q=(G )E/*H4[)JS2KF$^CD(A8MG,+ !&R0QBUZY#9=!==B>>41;MQB<46_
M\N4)4*=_Q"IA*.Q)ET?<UX LH]71=70U:\UW>%=V?OE^]Y.)4%,A2RS(/."2
MV(V(@$_(<W 2(DRP5.O;GO%*17<J/B%GC\E;JTYZRJ;>; \9#_>3#0I!CYR0
M"9%O!%^T=*[-+9F?\4HZ! C="X"'Y% @($RE#7?D?D.YVCYY+.S2W[FPF9$I
M8IBG&FD0H8[[2K9N3R#=#JRT'G>MOC8"R[*00>U4%&-FQ$1:!SQDN"7 I0SW
M2+$/VB#4>H?LQ0>)N/JB]]CAX6%O<'CT^O5O+^$!,9/:VV+!QGB?(Y.Y:3AZ
M)3P!?+=S<8^KJR9!IU):2R>]J,O#Z.*L+@TOZ<Q/7'EN%@ J%!;\G$\EZLP/
MM)QS0B0K.!F^M&Q%T&$?)8<DQ4RZ@N26Q%L*KD)$<8HO6T&<IXQ;(1>&\RB.
M>)9%: GTE65&%#Q<Q#I5MBF5"DX(RY+D<N.:F-UN% H(85O(4BJRX,>:Q(3\
MW[4)3J@#)RHDMF?N%I-UAUZ<A0.;UWS&9<'3(B!=+WAN+'D1N(K4(I4S5-FI
M<]7Q_OY\/M\#\'L3/=OK=LYT)45[],]9^C]C3F6,%S;479TZ+A65,BIWW4ZK
M?<+&1I=L:V)-V-756<*&5.+)/\?LXLY+MV"CA2*> @//!3F3=$QP,0[ B')I
M <AP)I2'<+KAWY"(\.T; OJ@_UN"($/)$X6HIEH%B%X,^H.7[*C_NO?FZ-6K
M4&T1B**$BO3Z]U$\]KJU^1QXS819O)NT:I,:R&UV#R ]\5R&<@6/V^ Y0>4<
MQ1HQI72@,=9)YRET5$W)X-; R+2)3 $%3F;(Z.'&T#U=69AZHGF+EGIMRYE$
MC22T5( YGAS9$L4TMEI.(1WVVP<2B+6%!71)R4??\<8B#H(B8!,Q2UF/'T&A
M9$U5$V7/M0<'3(GR%'P^]@70D#JH_R 9X-$=>)8<4Z31@T"1:@R6:D%&3%>D
M&IV]5;\G'1+#5'NWTCOL4/1'= ] T;B&\GWA=NIY;%]"VT;DZ<?M1[?S__<?
M3QK[5M0O:-\^2%'DQ^P:=/$MUM]Y ?L@%JU=W;Z?G%_^^V&KW7.Z.F:_5JX1
MW4NU<[JLGZ7: +[VV?N"@X(/JOMP-W*<?[U-W %MW6QG-XY8Z_)/]J'>%DU3
M(_AM+Q6HOS"G"N;]A/:/:K>IR7:-R3,]ZI6B>WZH[@K^^^2 B/G3#!JPPCDW
M>>\*;09=B5'#6^P.#SD3AFKVDA11'Z=B&:^3^&J]J+GDN%:MB*IU.\OM-<<,
ME*9N_HCL1=X<?KTV<D;)<X6\7N%C$O/O5Q'XVS +Y*W_YLW1'O%C)NXY-<K)
MLI-N^A9P@<Q;=!<Q:SLB.9,X8_!91B6P94#UQ*@E+RVW _/(9 6M\M#[8$/;
M]@3FLG5[$H8;%CM(UB.8[+$1U8RU%:N82S73!3493/DR1;:#!K=*SV.R\RI^
M1Z6YA2=IO!*\UA!_IBD=LC'Z4XW&/I3(;H>86<:;5JZ>)X 2^,)!"-IX CJ,
M*VCPD$VEF-7:U'@U ,>A2@EEC40E)\0#DP=E#.#0FK%WWHBMXL/\XX%\<1^H
M"4%I&%A5(6-78!]'J8&Q-E.JK/ Y(B)%7:/NC+@-4=PP3*EY:CL4BYP9Y"*5
M!;%+8NM1)^R' RE.0LP0,P!#R,!FO\<N!^;@+!-9%,B%;9BRJ%S$+X1+[C.R
MG.?U+ 4&G7T>Q29'X3I6?$%FP#$Z%T52!Q^H9S [/(R\GZH@,24EP$HD5<H'
MMC2=&B*/+ Y3)[*8@(Q$'OBBO2(=JH*'T1SU0!0\T*;;6<9/X' 4]BKT^76!
MC>N)[<9+&%J$1= 7#O6$OP_7)R0&0X(L>9+"0F;P?V#U:Z?4 1+PHWH_$P6%
M27OH4I/5D*8[9Z1PU+08.9DZNQ/ET*M'?S63O:4SH9-&XTPM5TM0 EW1*0U]
M;"8V/-X$1QZ&><(UXSC=)"#03[HU8BR@I70@VO "DF.Q3'NX73242QA:-V%4
M<".(JB]X%!;[>@IZ]CGP)Q.N;40)6;I,O;'1^U7@P^2"Z/+UUFWC2HA[\.$F
M'=9^RD4*>-.BU@_"6ML0F_45C+Z(TX"ZFZ<9 2Y3,_<3\((N%Z1J1!H-IS"S
MC>%)$G/W U$U7<3K7)0R2U;"(AH&1LA#^RS5-L.HMX95]D%W'8<3<_ EVQ2S
M%'T>PC&I*U>W4S_'J3&$7/NNV1)'9>M/<>V@_<938%MND4%7??T9E5Y)+>VZ
M+LL"M;ZED+>B6*P_M4+<ML]"6D->++AI4F^88<N<.N[QXK&4V^U\#=3<A@R+
M<D+1 ,@I\]"P&$PSC)4]Y?Y"QG1([D"E?$1ND\/0:O-;;* ;W-:=G-A!:,":
M]=T.S9]**!+]UXXL;>S7:/J^#-:@6.@D8K/I*Y)HXX"&YIRA,H652ZX38DBV
M[7(D'<O)=[=#-*/0-E:Y"<RJ!SQ6; 0FKL=FA .K6$%$-&Y%WIH6FY'<C,^W
M172R.22Z5"A:H4;:97+=)G?[! G9)4>31D..:-K&Z G^>'3V])1[L3,".W/'
M.Q1)&9D#]3LO4:SL+D5_HLN:<?;>&TK"U$SO4/H_^KW!0;_W:G#8>_7JS6"'
MDK^GI/"[E5#:H? FOM$LQ/JX4\AW'G&?P)51 S^(.*^ZDF,QRB0;YC-I<4EW
MZ4\&A_8'O3?]H][@Z-?7NW1H,.)= >4M2&FM^XX=NW/H_VZ!^_37%/'/*^BO
M,/X#4$L#!!0    ( $2#9%+@G\=\H L  ,DE   0    938R,#,U-%\Y.2TR
M+FAT;<U:6V_;.!9^-^#_P"T618.5G=AIVC3-%I,FZ;2S22?;9!;H(R71-FM)
M5'FQX_WU^QV2EN5+.AUL'E(@=4R1A^=^OG.4TX]WUU?ONIW3CY=G%_AD]._T
M[M/=U>6[T_WPB:?[\?'I^]\OOK+;NZ]7E_]\-E*5/6&#@]JR.UD*PSZ+.?NB
M2EXE82%AMT++T3,<Q-&;Y;F2Z[&L3MC!LW?/J]34;T_W;S:V_"SIMZPAAJT@
M>/K^G3P_NV!G5:5<E>'DC9:9K,9,C=C?A\/^ ;N612%5Q6Y<6LB,_3X:@9+?
MT.V<J[+$HUNKLNGI_OMWC\C9HXOZ^>SVXQ]G"?O\,6'77&<3=IBPX<%PP'H]
M1DI(V*<JZ[,7=B+8\R+_[M1;R%?S:O%<^V])MP,B%V?_/F&?L'\O89R-"Y7R
M@I4BEQD^K<@FE2K4>,$*P7.A6:W53.:D, D=S[B5,\$R#EUKE@OLMZ1<7N4,
M]VI>+YA1A:-%2&)5SA=X&(R3=SO$6[VR$*^8JW#+7$MK1<7J8".ULA$;),/A
MD'Z8F7 -?6%-6L.R8#I#IF/<0I3-PW2/\'XP..X?'+!:Z&['$^FS._ QULH8
MDB\3(O=TB;OFN%7^>U0APS$F[FO(*W)ZE@K&:QR^ER6WHEA$;RN#MR5X/E(X
MDHO<045$#\0:8;'0[>329% ,A"'UD4#2&%*<_ZY(GTP8ZR_(5XP1%Y41I@][
M,Y[GTOH+V\R.-:\\G^T[A09A+$EM%SW8I=M1M3<>I*D='(H;[*[I*U\1AE,,
M7@^2H\&KE@$VE>_-NDO]"=P(2F[+S1JQNYT-N?M/.?[(9;)"F>B7:[XBS9IO
MJ"QSFD%!2C.>*F>[G1"Q1R%B$V9<^@W;ETYF$%9FQ$,LD7X=5(O[%\V-F:J"
M/9ZVDGYUX[&H)D*6V  E@&6<AGIX" )N*#T(EBHU[6E75;0(LGQ,P8F(6=-K
MG_UV?=,BE+!SS>6X]Y$7A2O9.:^EA7_^JI6K$Q\T5WPJD,ZU$+9Y#-5/A<7A
MJZMS'\8K7BC'+:\WV_='DC(O^)P]YV7]MHFP%W_\:X]=V;SO]YPK1#W%5TOH
M[=LRU5O>Q;9$?<I6O6NE%HG$4B%=PG,=\@7)4$'9#Z71H-2YTE/OQ=$DI#/X
M">I% :WH6FFD.$I"M:+$]M1U8596SH7)M$P1]PAT5$:R>"I"CH &L)XNVJFY
MVX&4QB$]QSPKL"WS1=5,1#%B6HREL="'] D6>BD%-N/+!Z415;U#]N*#1 A]
M5GUV>'C8&QX>'1^_WH,%Q$PJ9U"*1GB>L[FT$W]URRFA^&[G\AZYOAI[GF+J
M92\B8KB]/(]H88_N_(U7CM+0X,!G+OP_GT@DL@>XG'/22%9P$GPE68O0X0 H
M)% B)U@O-'\N^_7EATWQCPZ/#X[WHLQMY7YQV/;RU?!%NA<*T(8RNITS9&""
M&&\. :7 .L=U*-@)W1@2]G"9L'\H=BHR'&7<4=*V!*1@A)7XKL9N\.<SVAD9
MJI"EK* .> - "!4.A\3HZKH(!+&#VQ8(:1(2*7C3NI?G6_QZW5+6G7%9\+3P
M)HB;GVM#YC5L+E(#5( J;-G$VOID?W\^G_?AW/VQF@6,-))DES]GDNZ+H;#$
M.L ;Y3:JF@,?$79:"1% (4GA':(PJMGT,^SWV?N M&0U([#D@>K:G0E;*(?H
M4J[(P30RON!05>1L)1O X4JX"&B1O;,0N '2-'IXT$+A<@GD5EFIA5V08\T%
M!,*GW^EQ7:XR1Q?16@1038:8[#:RW\B]I$W.].E%"\HT -A+R7?;ZV=%@D'4
MA@*#]X=60+ RJ!M:+T,D>(RSCI;C7:M*?JYJ*1I_^)%?^1SUE_5>HM& RZC4
M<EE1#,\G:"@:#TK82*N2[<0G'ADD[(Q:$)+GA%U^=]+"$K>+BOHBU*8+47-M
MB;\$:0==)0>,A>AG,U$Y4*?R\155#K]]1;8\&+Q.?.87A:@GJA*$DE\,!\,]
M=C0X[KTY>ODR(72(+:($B_3XU]MP[4TC[042Q4SHQ2_CAFWB G73]*&>)UXG
M)357A/YA,T&]!?H'A$&E+*%9A*IU4"RO@@W)H(;"1.F0$8 3T2=:OL3$[8VI
M(Q=;++UI9SU&E*$.)[A/QYLI\(3/*SAJ>"'B>;-&05;4ERQ">B<;?<,3 S?P
MC"#"0C 8YW,(&$HV6-6!]MSGFY0:,,#'D2-WE\JSOU9&L/3=\4*.R-%HP=>J
MJ(,56Z!A@AH6X>Z=_#UIESCS:6(UJGA$TA^1UJ%%;3WD@I$^<S-Q/$Q+_(2(
MJN'#TXYNY_\?=SQIW3>D_M;KL0]2%/D)NT$K\A;[OSLJ'B#+>KTX$SR]^/2?
M]?E=SZKZA+VJ[9)T+U46>">NI4I#?<W:^X)G4S:L[WULY+C_9A>Y SIJQ;WM
M(0#&X#9#@A5ZZPKL:^OD=!_L[> T176?]L+DY8357KR?X/Z'W&USLIMCLDS/
MR/^*8)X'V6WI?Y\,$'3^-)T&J'O.==Z[0K=.(7&[1+SF$2\Y%YI*]@I.4Z-<
MA2H>DWB[7L0^9119*P)KP&[-\=B_>/ 4 5$I>-6:V]QH.:/DV>[6\3$.^?<+
M^4_)FN;@S5&?^@\F[GE9$Y+PR**-=FBBY8RAEN*O3'(V,4R8X36#I(WYI,<O
M6],)#^B 6C)9$QSL=J@IQ[T/'T,^M)0-G>=F0X\M*_39+969AS<0XE8%];RL
M<F6*!$DC]6FEYB%!NBK\CNHTA?5I NPMO6Q$(Q(F92EM8EDE&)?QY60!CYSO
M"XTK:()3"^U1)V%=FJUE$REFD9M@6S_3]T8),UJ:G6KI&[)<^HX<"-/KA/:,
MG'6 !#]%'W8A-$.36,T Q H9T+?9H:6V.R[U&,4$>"]<#B]*74#SA(>H'[0$
M6M>'SDVOPU-TC];+%'G"<=B/T!5ITH,)@(H,^/=;Z#H-^FS<I0/R B ).X&K
M16V#@-Y+:#P-R7D>A\&0Z/SZUB,-5B&$:[[PJ+Q4N2B2Z'- JUYLOQC:-2J<
M!*XJ 2 CJ;BJ@&&B+,LF IY'$G-CH'E(3)H,N!\*YI4?1M0%]V\/<-H[#W&S
M<A\/^\C;*S]VBC4Y;"> '.+6-Q2+,&*&01WIW^D8@*0OZ9U&>[>0&>SO.X&-
M:Z*#!/T5T'M!7M)<NN*D[=%X#J@GK&_PM1Q/K-G-'?N+S$5S40:="MNR)1XA
M5TCJE!M,XQ&.2FG<:C(J\-W.FL67SN$G\+6PR]<(BDR;P;, 62EJT%S2,,$:
MFDXAGQ:K3(G@HK<*"1O#]KJ*4X&Q*WB@%<9,Y//LVD,N34SHJ"9D]C)UV@3K
MUQY#DY3!Y)N-WF9(B'L9NGW28313+E)H-RTB?Z#5B ;?C!&8!+<,XYD J?W,
M"M&T[)\%K*#*!1D@J!K]J="SK6%>3-AM2A%AXFDN2IDE+;<(<@%$<NKM*3IW
M"A8&16:M]P_#F#DPEED6P!2](?PQ65:[N(Q;@P?9K4=A<KM<[7;B<J@WFYN7
M[YTVURG6-]>H7$OJ@C?65W5I\TDAIZ)8;+%BA)@V6WU>0UXLN%[F7E\T94Y=
M^FCQP]+UQ:-YXQ,LR@EY ZQ'B8=>=@&<^O=BCE)_(7D(#C*'0K)\F.XRAZ$]
MYU.FJL(/=R*HR E1^*9M;1Q:@I%@OF:"'M^'@9V6L_JIRW+"0MM<311-F*XM
MUN8M*WSD?4@V+78 *JV)*B$3X(Y0Y,:0*D[GC-ATS&X'\;'#P^O8NXL@7(O@
M!A?;GAS?".YRZ&1KMM?M?/(#/*J19I5==]&-DS^V/K=$>LG1V-%@),CVX,B0
M[1YX/N7V[9QTG=F31R1)&9FC#__N)(J5>4S2OU&L9IR]=YJ2,/7?CTC]'X/>
M\&#0>SD\[+U\^6;XB)2_I<3P+RU/>LH^L8P7)+M0<!_9AEJ@!'X08<1U)4?B
M-I/L+)])@QA]3'LR&'0P[+T9'/6&1Z^.'UU1W[PHOQ00P0":1@F>NGDW".[3
MGV*%O\VB/^'Z'U!+ P04    " !$@V12(7?K;#X#  "-#   $0   &EC860M
M,C R,3 S,#(N>'-DM5;;<MHP$'UN9_H/JM^%[#"A@4 S"1DRM) ;39K)2T?(
M@JB1)5>2 _Q])5^ @,, :7F2=\\Y.I)W%S=/IA$'+U1I)D7+"RJ^!Z@@,F1B
MW/+N!O!TT.YV/7#R]=-'8'_-SQ""#J,\;(!S26!7C.0QN,01;8 +*JC"1JIC
M<(]YXB*RPSA5H"VCF%-#;2+;J0$.*S4"(-Q"]IZ*4*J[V^Y<]LF8N('09#*I
M"/F")U(]ZPJ1T79Z X--HN=B_M3/?]O1^TR3.1E][Q_J+]-;]C"^$D=)Y_&A
MJP<XZ@W(=7WR^"V847ZF+X*C4<AKOV<3/7X:QM59%[=_]B]N;N[.LBV;FCS1
M" /[*H1N>4O'FU0K4HW1@>\'Z*%O91W.RX"-*6?BN0P>U.MUE&8+Z!IR.E2\
MD*XBEQYB3>?*-LLVX)G0!@OR"A^:.6$9?(BRY"LH*X76,B@KH"%=P6E**F/Y
M@FS"X@]\Z >P&A3P1,,QQO&<,L)ZF$KGB1**5F8=;H/E4&AF,=6EA"Q50NNV
M3\_G#$9P&-'0E:J#!G[5/[#MQFE$A>E(%9W3$4ZX]?0GP9R-& T]8+ :4^-J
M3\>8T,UB1?UB(:0M<]MI><3%XIC9.K:!#TWWPAM*<OK#^@9N8?NK5-KE4%O:
M">$!%K:\;.E$K&0J$](1$RS=*V^D $#7-HD[EEVFE"9:!2])))J&5^)KNHX5
MU9:7FN_90$[,(6^0".8DX;MQ%E9**7F@N*3%M17-<DM'(&VRAGOY+4\S-^2\
M//:DZ*CEN9N$Q=OY98]6L6510)STAB9+;W[U-O*-"PFLR)K*VA"P(C*FRC!;
MH4N=GEEGQM&OE[8!;A_M ?0OCLSQ<-<C6PKE__&L/:>_?,B\/]"B0?+GU29J
MVN-*98!8:\9-(S(;[CU)4JD-%/<$"QYT(1@<V%E2F>IPX707$XL;V,U$P=O#
MQ,9!7>9"OT5R"[A@;VM@X]A_XQK2_4N)B'*CB\@[W:S_1^QO)]7:P\^K%QX:
MA9P0$E) 8<>U8F2[4EEF7F9$5RMU5RM![9UF]C.RMXM7Q4=D(HR:[5ZUR\3B
MX3WULOH5LE6I%*2L3-QWR?L<[%NRZS[>KM<FRB3M\B]02P,$%     @ 1(-D
M4J70,%HX"P  C8H  !4   !I8V%D+3(P,C$P,S R7VQA8BYX;6S-G6]/ZS@6
MQM^OM-_!VWFS*U%*BW8DF,N,N+TPJH8!EG+O[.YH-7(34R)2&SDIE&^_=ARG
MB>.3!%9KFQ?<WO@YSN/XA^W\._WTTVZ3HA?"LX31L]'T\&B$"(U8G-#UV>CK
M<GR^G"\6(Y3EF,8X992<C2@;_?3CG_^$Q,^GOXS'Z#(A:7R*OK!HO* /[ =T
MC3?D%/U,*.$X9_P'] VG6[F%728IX6C.-L\IR8DH4#L^17\__#Y"X_& :K\1
M&C/^]6Y15?N8Y\^GD\GKZ^LA92_XE?&G[#!BFV'U+7.<;[.JLJ/=4?FCPC^E
M"7TZE;]6."-('"V:G>ZRY&Q4V^WK\2'CZ\GLZ&@Z^>>O5\OHD6SP.*'RJ$5D
MI*-D+;:XZ<G)R:0HU=*6<K?BJ=['\43;J6H6I4F'ON8D2TZSPMX5BW!>='KO
M;A"HD/\;:]E8;AI/9^/CZ>$NBT?ZX!='D+.4W)$'5#3S-'][%B!EB>1@5&Y[
MY.3!;B;E?"+C)Y2L<4YBN:,3N:/I]W)'WY6;K_"*I",DE0(/L%TGC;K*H(EK
ML[>$)RR^H!]S;49[LB_^=GC^/S2@'N^\"?<LQ^F'S-<CG=N^)A\[XOLX]T=:
MC/+D8T>Z%OE_L9VW+;_[\-J/:RHW7HE/#8MDEXOYB\3:I*RB8P0N]E!,#&7=
M5>TL:M2;RM&<\7;;,U%O46=&HL,U>YG$)!%USX[DA['\,#Z:EB/V=V+3'W,F
M5@/GJRSG.,IU?45CSD:6\HEI3"K/N7:'>=33Q%(QB9B8H)[S<:H.I@I_X&QC
MW6W9=F8I_"-=5?'JX(A= $8;,DXRMN41>5??U-U"1ZETM$F%0BZK"!U_78Y^
M+#3H=ZWZSZ?)OA9GW2V60]L-H?F]J-?2CF:QJ\ZVF=)]72\+HJLMALR>UA(D
M-5ZZ^5SL/I86+E.\MC3"*'?5T59;NJ<;A4%TM<V1V=>5!DF1W\[^0K*()\]R
MF=_5FH;,>==;3+8(J&G" J%M#.:AIO4ZU-^1=2*G'&E$GOT2N;%C8 /TKB>#
M3MOF[& 5!X'.$(?@_%$/0E645YK.*=WB](X\,]X%45/FFAV;21.9NB8H4BS&
M0$"4%BFQ5R[^L17G]H2G;[UHM)2NZ0"LFH 8LJ 8L7L#,:GD(9!RSS'-$CFD
M]:+2ECH_)0',MDY/#%U0M #FX-.62A\"+\M'DJ;R'@*F_8.+3>R:&=BP24U;
M&10WH#V0G"("E2&AP7/Q(E?P8A$UL,DUO4^$6K:[**K$P8)D.AS(4A&&9)Q7
MGFHW,GI(:BE=,P18->DQ9$%Q8_<&$J/DJ-"'@LH%C0>!4NG\8&+8M$-2B@)$
MI.FL#Q"A]H_'99)%.%6.+L6VK*.1%JUK3$"[)BHM85"X0.Y 9%2 )J<("0";
M?Q',AT%34_I!IF75#DPE"Q 7TUL?+%+O$97YEO.&=W@.@J7.;O3VF*WN^0*Z
M('#I,=>Z$ZSD#5R\SDD7-$_R-_FTWO5VLR+<TL2VQ!4AD#E-AED>!!& *9,$
M)4-2AY308__KNPTTEX]*@HTR96XYL)MLLM#4!,2#U1C Q%Y;/+GJD8NY&*LX
M3A<T)KM?R!O8NI;.+1F S28:AB@@-NS. #A*,2K42,@]XG'+DPWF;\LDZID\
MVD*W@$!&FX28JH 0 :P!C)1JM%S,_<\M]WBWB 6TR4.BGD/O8074NT6FQW:3
M'$ <$$#=#@&.1!!J1OG':4$CQI]9[7&*.=N*(?%MSF)XY=(3Y1:M04UH M89
M$A!F0WP"L#5"#]0S+XC)=XB*"I"LP2-WYW$L#E=6_G.54#(%CX)5ZY:Q#KM-
MLBS"@'B"W0$4E<H#_0')&'1#PT)G]HX&S_RC,QN*SBQH=&8?0>?^E06%SO$[
M&GSL'YWCH>@<!XW.\8?0$=T?P+@S%Q]O^#U[M3T:#BJ]@-.V:L5F+PL/FI:W
M/F1D@%SGR!#_L!3+KAM^R]E+0B-X00W)O6 #F+:R8VC# \ANL(^B:KFLX_RC
M5"[<>_]@M,S/B-,T:1]NE"8\5)K&>@<:I?8/QBW+<IS^.WGN/&6WB[U 8C5L
M1:6A# \8F[T^;%0,$D'^3L%+=.6-$>L+;D:YNU>5+;;VKRK7"H- P>:H_:JR
MNMJB1'XZ6_+*"09&AV:QLZZVF*IZNE861D>W#;7ZN?@;%QI_?]0R+TUZ^\@H
M_.A!6^*JOR%SNL_-\B#Z'3!E]GTA0X7.Z_5\F2$CLP_HM3)G,[YIIYK@=4$0
M?6RZ:4W?NMQ+G_[&DUSL?\XVFRTM[QG9GE0$=*[ZNM.F[G>K* @&NIR9/)1:
MU!1[@6/)TB1*\H2N?Q4GJSS!MK;91*ZP@ UJ)MJ*((  ;9DT[(5(*[V@<,N)
M!)*([BA>4Y2IDOC-PX-U%= E=H5&OV&-"*P, I5>>R8R(F <U2*0"D%%3 CP
M++)L2_B[$+*$> ()- _@U-*'"!5DLA<M%>B?L"6)MF+>?)O.5O=)GMI.0]L2
M9[,48*Z:HXSR( @!3)E$%&6(/:#I[*^KOR$=Y06":W;/L4R/NWS;K%@*Y-.R
MJERAT&%1TV"1! $$[,MDXIJA4HJ4UE^^K89E2Z.,<E<86&UI !J%072]S5%K
M(&CTN-=)X&(7/0IK!'@UPBYS/1G83)H30ET3! @=QEHG+J44::V_5R/V4]FZ
M?W&P]K8X6/<L#M8A+@[60Q<':\^+ [USE>A$C%0WJS198R !8Z?:-1H=EDU*
M+-*@@(']@>-'%8+V,7YR=Q8)W.07%/!-X>)2?+"T%= YR][99;-*WVD3!4%*
ME[-6 D^54J\F1E+MAXYMG.0D5I8N$XIIE."T2@1INZ;>'^*,F8'F*WQZ]&&0
M-,QD"RH5IO,U5H'[I)Y^+L:KQSQ^(VGZ"V6O=$EPQBB)U148VWVG;KW;YW)Z
M;#<?S0'$04 UQ"'P@(X,&C_)**3#RNMG'GGZQM(MS3$OWG_GME$*T+GE![#9
MY,80!<2+W1G 225&2NWS=7*5_:):@JEO9 *;"<D=OUS>:=IXQ]RJ#8B<3H/0
M&^=ESI+]REE%>7T)-"?RFS22%_(%Y[AT"+8:DKM^[;/+M/F^ITT;$$B=!L$W
M/*L8F? &:[(\)[[A<[$06[..)]4-E?OT-RV+[0PXE20@2&R^.O+@<*2U'HE8
M;G":?MYF"249/#49*K=$6"TVB6A( B+"Y@L@HI BK?5(Q,6&\+68]G[F[#5_
M++/2@BT$U&X)Z;3<),4J#8B8+G\ .3H$J1B=2-@G0KM]8G653Q)NKT7J&![0
MK$%.2Q<2-I"Y%C,IB>3UF6N6HWN&OF8$Y8\$791?WU?/B*_J\?L=+%$D7]!0
M*W<:8VX#J4OL_/M80,.M;V5I*8/ J=<>_ TM5032(5[8N1$\\_H97V%ED9,-
M^-Y%?X@KCH::US3UZ8-@:J!)DZPBK'D:7@0B&>D_,U,]U3^\ &R('*^;+0:-
M97--$00IH"UHT5S_Y@2?F0&WJS2)+E.&X:LR#8WC?(!M>T8JP+T@( [:KJ $
M@(40%4J/%'S&](EOG_/H[9:SB!#Y1%=6C5]]5^T&1KLEYUU-:C(U*#0@VM[C
M%^!P7P6JU7%0F\/\7P*4#Z[+7'4L>EH^8G$8;[9Y)F=680^^CMX9Y/@&Q8 &
M&+<I.B(" G" 3>B611&)BM #I()1+=KK.5RVSW1(XL]O=^2!</D&Q#W9Y9_%
M[IXZSD(&Q+H^PQO<'/.$KS<P"!3?ZQ8Z'<Q0O0*TDD^BE56@WV4EJ*C%SW?#
MZWLZC:>D"+\B:YS><)6/7'B-.[/##PUW?=?M/8TR[\(-B0T"TP\8!N_2574<
M(%4+*JJ1V:7V%4'/7]<W78E/8K/>)'ZM<$;$EO\"4$L#!!0    ( $2#9%+;
M\PPN= <  .E:   5    :6-A9"TR,#(Q,#,P,E]P<F4N>&ULS9Q-<]LV$(;O
MG>E_8)6S/MVDM6,W8RM61A,G=BTG:7O)0.1*PA@$-"!H2?^^ "DI^B# ]25K
M'VR97 #[/@N!7 +@^;ME*J(GT!E7\J+1;74:$<A8)5Q.+QI?1LW+47\X;$29
M83)A0DFX:$C5>/?7K[]$]N?\MV8S&G 0R5GT7L7-H9RHM]%GEL)9] $D:&:4
M?AM]92)W1]2 "]!17Z5S 0;LB;+AL^AUZTT<-9N(:K^"3)3^<C_<5CLS9G[6
M;B\6BY943VRA]&/6BE6*JV]DF,FS;66=96?]4Q8_%UP^GKE?8Y9!9&G)[&R9
M\8O&3K.+DY;2TW:OT^FV__ET,XIGD+(FEXY:#(U-*5=+5;GNZ>EINSB[,3VR
M7(ZUV+1QTMZXLZW9GN4!^QU/,GZ6%>[=J)B9(NBUS41>"_=?<V/6=(>:W5[S
MI-M:9DEC [\@J)6 >YA$[J\-WK95'K,DA<3%J^W.M?O*]D;K:%%JIF%RT7 V
MMO)>MW/2Z;FJ7^T9F=7<]LJ,NT[5B-I[S<XU9"!-H?3&'M@K DMC.Q,DFXI<
M^TC'##?.=MU5NE'3]:L\M4W9CZ7EVH^-)T+%>XT+QU\=*'5M9[;Q@G(&<6NJ
MGMH)<$N[UW$?'(9.L]-=,WYE#WTOFKL<9T:SV&SJ$VP,HFCEN[4Y,&G_--\V
M5!YLO=6N[5L<>K8;OTL=1THGH"WW35U,QWM1.^ZB:XOVG&E;43.><;$-^$2K
MU,=HS4-Y'-W%99OXF4POK1>)\V0@V+0:ZH$)DFJ7 FNE&EJN[R&+-9\[.C5X
M]RR1E'NDE"NTD<#>?)ON8<J=U\XA=RD&=S \4GB*(/&?4(X=0;6D<;B4,F?B
M'N9*U^#?MT12_YV2>I4V4MA_YTP;T&*%X7UDC$3^FA*Y1R$I]0?-9,8=)0SV
M8VLD]S>D-R<>C:3@1S,0PB5]3*)Z?)4]$OX?E/#].E\,_NLG=P]@+SSX".P4
M00;ASY<2A".UI'&X \U58B_[&A&!(V,D^U-*]AZ%+X#ZM4RPS+>FZ*R)'OF!
M/%+@ Y[%3)1^#>RQ+ R]PAP+GB1?K97Y N#_"TRCT>\88\&3I+ U$DFP]W.M
M]UP*CC-^:RQXDN2U3B0)^6MIN%FY^83/>3K^\6!VG_BQ%98T2<+J$T5(>//$
M0AHW71*B?&B))4V2IX;$$=+N6U6:B:%,8/D15B'<1Z98WB3Y:5 >(? [S5.F
M5R,>UP\CQ[98Y"19:5@@(?,'MAPF5AN?\'(*LAZ]MP@V B0I*4HN82"&,E9Z
MKG8>1_=5;K^AJ[Y*@D-]34%L4$ARU6=()PS-99)8:-GZSPV7T T%I-(</1]%
M%X: S!<%O_<\^#T\?)(<ME;FBX)_\CSX)WCX)'ELK4QZ^'W[\58_J(5G_MMK
MC 5/DL?62*3'7ER';O6=5D^\7*U5Q_ZH!#8 A.EM6"Q]%-8W IB>O['$4B=,
M=:O%T=.^4YEAXC\^K[OGK+;'DB=,>D-":1Y:EGW /?SP+7 Z,,%2)LES*^70
M@'71UL#\77G? HN5)'FM$D-"]4:Y>9:9DL$GO<=66+HD6:A/%,V [-9!9][!
M8.<T>HT=R7![*(,$YC?-C?6CK](TE^LG/IYY.(\I%C))ZAB41P)\I 2/N>%R
M^LG>46K.1#7M*CLL:I)$T2^,A/.=!A=UL#?KQ4HSMW5"WTXFOA$Y9(_E3I(G
MU@M]"?R'69:#?FX4*DIA8T&2,F)%TXP\$.=V.%QU>^,'MQ_(,^X<66&)DZ2+
M/E$DA#^K!\W<7L31*ATKX=_P4FF(Y4R2' :DD:#>\Z8:\H$)%B])5E@IAW24
MN%[&,R:GX%]'46V)Q4R2)8;$$8_)4]28/'WFF$R2+?I$D1(N5[C;[]CM6/ I
M\^^6"Q9 [Q^BY!Z02K-3L=C0Y':QZ[3P9F _5,/WF&*QTVP)#<FC 9XGW$!2
M.C;@DLG8IF/;'7R>_+Z^%#8,-'M&D:())Q&^@1 ?I5K($;!,24C*!"$TC^ M
M@HT%X=QEC5S"0'Q5(K>L=+%X57N^#QY3+'C".4N//,J5HN6B[.V5J7R-28B[
MKP06/^'D95@LZ0HZ \YS_@3OF6%K/T-1\)7 1H%P(C,LEG@7@.[;R])4A>?M
M#PRQS F7[U9*(T0]2ID05WG&)63!T>; $(N:<)UNI31"U-<IZ*D=[#YHM3"S
M]8[6$')/ 2QZPM6X0:F4(5C^V$]?[O0+\J^P1K^K@1"^5R3M"TGBV"WL**_V
M,F':PSYDCZ5/NI'4+Y2$_ZV9@=Z]TRI<&MJ<+[3\HKX4-A8DJ2Y6-.65=^>]
M!L$+[YX=ECIA4ELEC')'6#X6/!X(Q8+W\7MF6,J$&6R%+$+(5TP^ZGQNXM6=
M5C& FZK)MM\_1!J%K  ;&,+<]EDH*!\XJ#1U6Z54_#B:6>G9;6Z*M\):+X./
M'8+EL &BW+2*$$YZIY3]V,P&R=7J'B:@W8*)!UB:*]O<8_C&"5$<&R72MR^A
M,9 ^+]J;TP!] U,F;G6Y$=WZF]3MLL?6@ T98<+]/!@543MO'TF[L0?<6YO+
M,^Z7>S.Q/?(_4$L! A0#%     @ 1(-D4NTEMJ>SK@  L/0#  \
M     ( !     &4V,C S-31?,2TQ+FAT;5!+ 0(4 Q0    ( $2#9%*C$C#%
MW @  ,4B   /              "  >"N  !E-C(P,S4T7S4M,2YH=&U02P$"
M% ,4    " !$@V12G^%C7/06  !0=   $P              @ 'IMP  938R
M,#,U-%\X:RUI8V%D+FAT;5!+ 0(4 Q0    ( $2#9%+/QIB\. H  (PA   0
M              "  0[/  !E-C(P,S4T7SDY+3$N:'1M4$L! A0#%     @
M1(-D4N"?QWR@"P  R24  !               ( !=-D  &4V,C S-31?.3DM
M,BYH=&U02P$"% ,4    " !$@V12(7?K;#X#  "-#   $0
M@ %"Y0  :6-A9"TR,#(Q,#,P,BYX<V102P$"% ,4    " !$@V12I= P6C@+
M  "-B@  %0              @ &OZ   :6-A9"TR,#(Q,#,P,E]L86(N>&UL
M4$L! A0#%     @ 1(-D4MOS#"YT!P  Z5H  !4              ( !&O0
L &EC860M,C R,3 S,#)?<')E+GAM;%!+!08     "  ( /P!  #!^P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
